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ABSTRACT 
 
 
 
The neuronal ceroid lipofuscinoses (NCLs) are the most common group of 
neurodegenerative disorders in childhood, with an incidence of 7-8 per 100,000 live 
births. They are recessively inherited lysosomal storage diseases caused by mutations 
in six different genes. A few years of normal development is followed by progressive 
motor, mental and visual decline, confinement to bed and severe disability, further 
complicated by frequent epileptic seizures and ultimately premature death. One of the 
subtypes, CLN5, also known as the Finnish variant form of late infantile neuronal 
ceroid lipofuscinoses, is caused by mutations in the CLN5 gene, identified in this study 
by positional cloning. CLN5 encodes a lysosomal glycoprotein whose function is so far 
unknown. The CLN5 disease is enriched in the isolated Finnish population and so far 
29 patients have been diagnosed in Finland, one in Sweden, and one in the 
Netherlands. Four different mutations have been identified and the most common one 
is found in 88% of the Finnish disease chromosomes. The carrier frequency of this 
major Finnish mutation is 1:24-1:44 in the high-risk area in Western Finland, where 
clustering of the ancestors' birthplaces has been demonstrated. When analyzing eight 
patients with different mutations, no correlation could be observed between the 
genotype and the clinical phenotype. Thus it appears likely that each of the four 
mutations severely disturbs the normal function of the protein, and results in functional 
null alleles.  
 
We have isolated the orthologous mouse Cln5 gene and analyzed its spatiotemporal 
expression in the central nervous system by in situ hybridization and 
immunohistochemistry. Cln5 was expressed throughout the embryonic brain and the 
expression steadily increased during development. In the adult mouse brain, prominent 
expression was detected in the cerebellar Purkinje cells, in the cerebral neurons, and in 
the hippocampal interneurons. These findings are well in line with the brain imaging 
and pathological findings in CLN5 patients, the hallmark being the severe atrophy of 
cerebellum. In vitro expression of Cln5 in COS-1, HeLa and neuronal cells indicated 
that mouse Cln5 is a soluble lysosomal glycoprotein, closely resembling human CLN5. 
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REVIEW OF THE LITERATURE 
 
 
1. HUMAN GENETICS 
 
1.1 The Finnish Disease Heritage 
 
According to current knowledge, Finland has been inhabited without interruption since 
the end of the latest glacial period approximately 10,000 years ago. The dual theory of 
the population history of Finland, supported by analyses of Y chromosome haplotypes, 
assumes an early migratory wave of eastern Uralic speakers some 4000 years ago, 
followed by more continuous immigration of small groups from the South and West 
during several thousand years (Jutikkala and Pirinen, 1996; Kittles et al., 1998; Norio, 
2003b). The majority of the genetic profile of the current Finnish population originates 
from Western Europe, suggesting that language replacement occurred when the 
"genetic founders" arrived in the area where the "Finnish speakers" had already 
stabilized an agricultural lifestyle (Sajantila and Pääbo, 1995). Both maternally 
inherited mitochondrial sequences and paternally inherited Y chromosome haplotypes 
show an exceptional low level of genetic diversity of the Finns as compared with other 
European populations (Sajantila et al., 1996). The reason for the relative isolation of 
the Finnish population is mostly geographical and geopolitical, explained by its 
position between Sweden and Russia, two powers with distinct cultures, languages, and 
religions.  
 
Around year 1500 AD the population of Finland was approximately 250,000 and was 
heavily concentrated along the coastline (early settlement; Figure 1). However, an 
internal migration movement began in the 16th century from a small southeastern area 
(southern Savo) to the western, central and finally eastern and northern parts of the 
country (Figure 1). During the regime of the Swedish king Gustavus Wasa in 1523-
1560, inhabitation of the wilderness close to the Russian border was highly favored. 
Reasons for the internal immigration were also the need of new land for cultivation and 
the avoidance of increasing taxation by the Crown. This late settlement, aided by the 
founder effect and by genetic drift, shows clusters of regional isolates with a very 
homogeneous genetic background and an overrepresentation of certain rare alleles. 
(Norio, 2003a) 
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Figure 1. The internal migration movement of the 16th century resulting in regional 
subisolates. Modified from Peltonen et al., 1999. 
 
 
The Finnish Disease Heritage (FDH) comprises at least 36 monogenic diseases: 32 
autosomal recessive, two autosomal dominant, and two X-chromosomal (Norio, 
2003c). The disease spectrum extends to all branches of medicine but is most visible in 
paediatrics. A study of 2151 samples from different parts of Finland showed that, on 
average, one in three individuals was a carrier of one of the 31 most common 
mutations (Pastinen et al., 2001). The total incidence of the FDH disorders is 1:1,000, 
meaning approximately 60 new cases every year in Finland per 60,000 annual births.  
 
The FDH has its origin in the special population history of Finland. The small number 
of original founders, followed by isolation and rapid expansion, formed a unique gene 
pool. The frequency of some rare diseases became overrepresented, whereas some 
disease alleles that are relatively common in other countries became very rare. One of 
the most striking example is phenylketonuria (PKU), with an incidence of less than 
1:100,000 in Finland compared to about 1:10,000 in most of Northern Europe 
(Guldberg et al., 1995). In Finnish subisolates, the small number of founders inevitably 
resulted in consanguineous marriages, although the relationships were typically remote 
and unknown to the individuals concerned. This random inbreeding increased the local 
incidence of rare recessive disorders and in some Finnish diseases a strong regional 
clustering of cases can still be observed. A typical feature of the FDH disorders is that 
one disease mutation is found in the majority of the Finnish disease chromosomes, for 
many diseases in more than 90% of the chromosomes (Peltonen et al., 1999). 
 
EARLY
SETTLEMENT
LATE
SETTLEMENT
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Of the 36 Finnish disorders, the genetic loci have been established for 33 and the 
defective gene characterized for 27 (Norio, 2003c). This has been possible thanks to 
the peculiar population history, the reliable and well conserved population records kept 
by the church, the smooth collaboration between clinicians and researchers, and 
especially the positive attitude of the patients and their families towards research. The 
FDH has proved to be valuable for developing the strategies for identification of 
disease genes, and several novel genes and pathological mechanisms have been 
characterized. For the monogenic Finnish diseases, interest now focuses more and 
more on the proteins and their functions. However, the knowledge accumulated can 
now also be used for studying hereditary components of common multifactorial 
diseases in isolated populations (Peltonen et al., 2000; Varilo et al., 2000; Laitinen et 
al., 2001). 
 
Four of the neuronal ceroid lipofuscinoses belong to the Finnish disease heritage. 
CLN5 and CLN8 are typical rare Finnish diseases with only 20-30 patients identified 
in Finland, while they are almost non-existent elswhere. CLN1 (INCL) is strongly 
enriched in Finland with about 170 pateints diagnosed here, compared to about 200 
outside Finland. Approximately 200 CLN3 (JNCL) patients have been recognized in 
Finland, but the incidence (1:20.000) is almost as high in several other populations. 
(Norio, 2003c)    
 
1.2 The Human Genome Project 
 
The sequencing of the human genome has been a huge step towards understanding 
human evolution, the causation of disease, and the interplay between the environment 
and heredity in defining the human condition (Lander et al., 2001; Venter et al., 2001). 
The fundaments for decoding the mechanisms of inheritance were laid  in the middle of 
the 19th century when Charles Darwin presented his theory of natural selection 
(Darwin, 1859) and Gregor Mendel established the laws of inheritance, based on 
experiments in plant hybridization (Mendel, 1866). 
 
Milestones along the way have been the recognition of DNA as the hereditary material 
(Avery et al., 1944), the determination of its structure (Franklin and Gosling, 1953; 
Watson and Crick, 1953), the cracking of the genetic code (Nirenberg, 1963), the 
development of recombinant DNA technologies (Jackson et al., 1972; Cohen et al., 
1973), and the establishment of powerful methods for DNA sequencing (Sanger and 
Coulson, 1975; Maxam and Gilbert, 1977; Smith et al., 1986) and amplification (Saiki 
et al., 1988). Thereby, the stage was set for the official international Human Genome 
Project to begin in 1990.   
  
The goals of the international Human Genome Project (HGP) were to identify all the 
genes in human DNA, to determine the sequences of the 3 billion base pairs of the 
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human genome, to store this information in public databases, to improve tools for data 
analysis, and to address the ethical, legal, and social issues (ELSI) that may arise from 
the project. In April 2003, the Human Genome Project celebrated the completion of the 
full human genome sequence and Francis Collins announced that all of the initial 
objectives of the HGP had been achieved at least two years ahead of expectation. 
(Collins et al., 2003)  
 
The concrete results of the HGP are the production of a genetic map and the 
sequencing of the human genome, the sequencing of several million expressed 
sequence tags (ESTs) representing transcripts of the vast majority of human genes, and 
keeping all this data available in public databases. During the project, several 
technological improvements were accomplished making PCR, sequencing and 
genotyping more effective through automation and miniaturization. New methods, 
including capillary-based sequencing, analytical methods for single-nucleotide 
polymorphism (SNPs) detection, and microarrays for transcript profiling have also 
been developed. The progress in bioinformatics and biocomputing has been invaluable 
for analyzing the rapidly expanding amount of information produced by high-
throughput genome-wide strategies.  
 
With all these resources now available, we have entered the genomic era and the 
potential of the HGP could be used to improve human health and well-being (Collins et 
al., 2003). Challenges for the future are to understand the geography and function of 
the genome, to characterize metabolic pathways and protein interactions, to monitor 
the spatiotemporal expression pattern of the human genes, and to develop genome-
based approaches for diagnostics and predictions of individual drug response. Detailed 
characterization of the heritable variation in the human genome is needed to increase 
the understanding of traits and diseases with more complex origins, involving the 
interplay between multiple genetic and environmental factors (Peltonen and McKusick, 
2001; Gabriel et al., 2002).  
 
1.3 Identification of Human Disease Genes 
 
Once the role of genetic factors in the aetiology of a disease has been established, there 
are several different approaches to identifying the defective genes. Functional cloning 
refers to the isolation of a disease gene based on knowledge of the biochemical defect 
underlying the disease, i.e. by purification of the defective protein and characterizing 
its amino acid sequence. The candidate gene approach also requires information about 
the pathogenesis to enable sequencing of those genes most likely to be causing a 
certain disease. However, experience has shown that the prediction of responsible 
genes based on the phenotype is very difficult. Thus, the development of map-based 
positional cloning was a breakthrough for medical genetics. With this strategy, disease 
genes can be cloned solely on the basis of their chromosomal location, and no 
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knowledge of their function is required. The positional candidate approach, a 
combination of the last two strategies, has proved to be useful as well. It is based on 
mutation analyses of the most promising genes in a well-defined chromosomal 
location, when the critical region is too big to allow sequencing of all the genes in the 
region.  
 
Positional cloning has been a time-consuming but reliable method for identification of 
the genes underlying monogenic disorders. It includes several steps, beginning with the 
collection of blood samples from the families and ending with the detection of the 
mutations (Figure 2). The technological development and the accomplishments of the 
HGP during the last decade have drastically reduced the time needed for positional 
cloning of disease genes. 
 
 
 
Figure 2. The different steps of the positional cloning strategy in the Pre-Genomic Era and in 
the current Genomic Era. Physical mapping and transcript identification is no longer needed as 
the Human Genome Project has made this information available in public databases. 
 
 
The first step in positional cloning is the assignment of the locus of a disease gene to a 
specific chromosomal region. After collecting a sufficient family material carrying the 
inherited disease, the family members are genotyped with a set of polymorphic 
markers covering the whole human genome in order to be able to establish linkage 
Linkage analysis 
Collection of family material 
Fine mapping, linkage disequilibrium analysis 
Physical mapping 
Transcript identification
Detection of mutations 
 Pre-Genomic Era               Genomic Era 
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between the phenotype and a certain genetic locus. The development of dense DNA 
marker maps, sophisticated statistical methods and linkage analysis software have been 
essential for making positional cloning a useful tool for mapping the genes that are 
defective in human diseases (Weissenbach et al., 1992). 
 
In isolated populations, linkage disequilibrium (LD) and haplotype sharing can be used 
for restriction of the chromosomal region defined by linkage analysis. It is based on the 
assumption that the patients share the same haplotypes in markers close to the 
mutation, as one single disease-causing allele has been inherited from a common 
ancestor. LD and the recombinations observed in the disease haplotypes often allow 
finer genetic mapping of the locus of interest (Hästbacka et al., 1992; de la Chapelle, 
1993).  
 
Previously, physical mapping followed by transcript identification were the steps, 
which could easily take several years (Figure 2). Howerver, thanks to the Human 
Genome Project, these steps can now be replaced in a few seconds by a single database 
search on the net (Genome Browser: http://genome.ucsc.edu/). Physical maps were 
constructed by assembling contigs of i.e. YAC and PAC clones over the critical 
chromosomal region. Subsequently, the coding sequences of the PAC DNA were 
identified by cDNA library screenings and database searches for expressed sequence 
tags (ESTs).   
 
When the critical region has been restricted to contain only about ten genes or less, 
mutations can be detected by PCR amplification (Saiki et al., 1988) of patient and 
control DNA followed by automated fluorescent sequencing (Sanger and Coulson, 
1975; Smith et al., 1986). Currently, cycle sequencing is commonly performed using 
BigDye terminator chemistry and ABI Prism DNA analyzers (Applied Biosystems).  
 
1.4 Functional and Comparative Genomics 
 
The genomes are dynamic structures, continually subjected to modifications by the 
forces of evolution. Extant animal, plant, and microbial species are the result of 
hundreds of millions of years of trials and errors for acclimatization to the terrestrial 
environment. A correct interpretation of the message written in the human genome 
requires a parallel understanding of the similarities and differences of genomes across 
species. Comparison of DNA sequences from different species has emerged as a 
powerful tool for identification of the functional elements in the genome. 
Characterization of the mechanisms of mutational processes is essential, as mutations 
both drive evolution and cause inherited diseases.  
 
The first genome of a self-replicating free-living organism to be sequenced was the 1.8 
million base pairs genome of the bacterium Haemophilus influenzae (Fleischmann et 
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al., 1995). The nematode Caenorhabditis elegans was the first animal and the first 
multicelluar organism whose genome was sequenced (The C. elegans Sequencing 
Consortium, 1998). This 1 mm worm consists of 959 somatic cells and a total number 
of approximately 20,000 genes. It reproduces sexually and has a nervous system that 
includes a simple brain. Thus it has proved useful for studies in developmental biology 
and neurobiology.  
 
The common fruit fly, Drosophila melanogaster, has been an important model 
organism for experimental genetics and much knowledge about the fundamental 
mechanisms of genetic variation and the inheritance of specific traits has been 
generated by Drosophila research. Sequencing of the Drosophila genome revealed 
approximately 13,600 genes (Adams et al., 2000). A survey of 269 sequenced human 
disease genes showed that 177 of them had orthologs in the Drosophila genome. This 
emphasized the potential of comparative genomics and the role of Drosophila as a 
model organism for studies on human diseases.  
 
The most important model organism for biomedical research, however, is the 
laboratory mouse, Mus musculus. The sequence of the mouse genome provides a key 
informational tool for understanding the human genome and human diseases 
(Waterston et al., 2002). Its unique advantages include a century of genetic studies, a 
profound knowledge of mouse anatomy and physiology, numerous inbred strains, 
hundreds of spontaneous disease models and developed techniques for engineering of 
the genome through transgenic, knockout and knockin strategies.  
 
In the roughly 75 million years of evolution since the divergence of the human and 
mouse lineages, the process of evolution has altered the genomes unevenly so that 
functionally important elements can be recognized based on their higher degree of 
conservation (Waterston et al., 2002). By comparing the extent of sequence 
conservation, the proportion of the mammalian genome that is under evolutionary 
selection can be estimated to be about 5%. Such a high proportion cannot be explained 
by protein-coding sequences alone, implying that the genome contains many additional 
features such as untranslated regions, regulatory elements, non-protein-coding genes, 
and chromosomal structural elements. The mouse genome is about 14% smaller than 
the human genome (2.5 Gb compared with 2.9 Gb) and over 90% of the mouse and 
human genomes can be partitioned into corresponding regions of conserved synteny. 
The mouse and human genomes each seem to contain about 30,000 protein-coding 
genes. Approximately 80% of the human genes seem to have one single identifiable 
ortholog in the mouse genome. On the other hand, the proportion of human genes 
without any detected homologous gene in the mouse is less than 1%.    
 
The number of genomes undergoing sequencing is increasing as the techniques are 
becoming faster and more reliable. So far draft sequences are available for hundreds of 
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viruses, tens of bacteria, and several plants, fungi, and animals. The number of genes in 
different species has been a surprise for many - the human has only twice as many 
genes as the worm or fly, and notably less than the rice with approximately 50,000 
genes. However, the human genes are more complex, with more alternative splicing 
generating a larger number of protein products. The mechanisms of regulting gene 
expression may also be more sophisticated in humans than in many other species. 
(Lander et al., 2001)   
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2. NEURONAL CEROID LIPOFUSCINOSES 
 
2.1 Historical Background 
 
In 1896 Bernard Sachs used the term amaurotic familial idiocy (AFI) to describe a 
progressive neurological disorder with infant onset, psychomotor deterioration, 
blindness, and early death (Sachs, 1896). Fifteen years earlier Warren Tay had noticed 
that a retinal red spot was associated to an identical disorder, which thereby became 
known as Tay-Sachs disease. In the beginning of the 20th century neurologists, 
neuropathologists and ophthalmologists from different countries described AFI-like 
disorders in several families with clinical and pathological features clearly distinct 
from the classical Tay-Sachs disease (Batten, 1903; Spielmeyer, 1905; Vogt, 1905; 
Jansky, 1908; Bielschowsky, 1913). Despite the broad clinical variation, this spectrum 
of disorders was considered to belong to the same etiopathological process until the 
1960s. Eventually, the storage material in Tay-Sachs disease was characterized as 
GM2-ganglioside (Svennerholm, 1962), whereas accumulation of material resembling 
ceroid and lipofuscin was found in Batten-Spielmeyer-Vogt disease (Zeman and 
Donahue, 1963). Thereby it became evident that the amaurotic family idiocy disorders 
could be divided into two main categories, gangliosidoses and ceroid lipofuscinoses, 
and the term neuronal ceroid lipofuscinosis was introduced (Zeman and Dyken, 1969). 
More detailed descriptions of the history of the NCL disorders have been presented in 
several review articles (Haltia, 1975; Rapola, 1993; Goebel et al., 1999).   
 
2.2 Classification and Nomenclature 
 
The neuronal ceroid lipofuscinoses (NCLs) are progressive encephalopathies with 
autosomal recessive inheritance, characterized by neural and extraneural accumulation 
of ceroid and lipofuscin-like storage cytosomes (Santavuori, 1988). Collectively, they 
are the most common cause of childood neurodegeneration, with an average incidence 
of approximately 7-8 per 100,000 live births (Rider and Rider, 1988). The main clinical 
features are progressive mental retardation, ataxia, myoclonus, visual failure, and 
epileptic seizures (Santavuori et al., 2000). Based on the age at onset, the NCL 
disorders were originally divided into four main types: infantile, late infantile, juvenile 
and adult (Table 1). Since then, three variant forms of the late infantile NCL have been 
described. Atypical forms of juvenile and adult NCL have also been found, and 
Northern epilepsy has been shown to belong to the NCL group. 
 
In addition to the clinical observations, the diagnosis has traditionally been based on 
electron microscopy (EM) analyses of biopsy specimens and blood samples (Goebel et 
al., 1999; Goebel, 2000; Tyynelä and Suopanki, 2000). The ultrastructural patterns of 
the lysosomal storage materials found in NCL are granular osmiophilic deposits, 
curvilinear profiles, fingerprint bodies, and rectilinear profiles (Table 1).   
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Table 1. Classification of the NCL diseases based on the clinical course and the 
histopathological findings. GROD, granular osmiophilic deposits; CL, curvilinear profiles; FP, 
fingerprint bodies; RL, rectilinear profiles; EPMR, epilepsy with mental retardation. *Turkish 
variant late infantile NCL was originally given the locus name CLN7, but in some families 
mutations have recently been detected in the CLN8 gene. (See chapter 2.3 for references.) 
Clinical onset Disease Ultrastructure Gene 
8-18 months Infantile NCL GROD CLN1 
2-4 years 
2-7 years 
2-8 years 
1-6 years 
Classic late infantile NCL  
Finnish variant late infantile NCL 
Czech variant late infantile NCL 
Turkish variant late infantile NCL 
CL 
FP+CL+RL 
FP+CL+RL 
FP+CL+RL 
CLN2 
CLN5 
CLN6 
CLN7/8* 
4-8 years 
6-10 years 
Juvenile NCL 
Juvenile NCL with GROD 
FP+CL+RL 
GROD 
CLN3 
CLN1 
5-10 years Northern epilepsy / EPMR CL+GROD CLN8 
11-50 years Adult NCL mixed CLN4? 
 
 
 
Table 2. Classification of NCL diseases based on the defective genes and proteins. (See chapter  
2.3 for references.) 
 
 
In the last decade major advances have occurred in the understanding of the molecular 
pathogenesis behind the NCL disorders (Gardiner, 2000). Mutations in six different 
genes have been detected and the corresponding defective proteins have been identified 
and analyzed. This has made possible a clear and exact classification of the NCL 
disorders, based on the defective genes and proteins (Table 2). In this thesis I will use 
this classification and consequently refer to the diseases according to their defective 
Defective gene Defective protein Clinical phenotype 
CLN1 PPT1 
(lysosomal enzyme) 
- infantile 
- later onset up to adulthood 
CLN2 TPP1 
(lysosomal enzyme) 
- late infantile 
- later onset up to juvenile 
CLN3 CLN3  
(transmembrane protein) 
- juvenile 
CLN5 CLN5 
(lysosomal protein) 
- late infantile (Finnish variant) 
CLN6 CLN6 
(transmembrane protein) 
- late infantile (Czech variant) 
CLN8 CLN8 
(transmembrane protein) 
- Northern epilepsy / EPMR 
- late infantile (Turkish variant) 
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genes (CLN1, CLN2, etc.). In future, when the pathological mechanisms are 
characterized in detail, it might be more suitable to name the diseases according to the 
functional defect of the proteins (PPT1 deficiency, TPP1 deficiency, etc.). However, as 
different mutations in the same gene can cause a broad spectrum of phenotypes, the 
clinical course cannot be predicted from the defective gene alone. Subgroups of each 
NCL disease can be defined according to the phenotypes that the different mutations 
cause. 
 
The medical literature has a strong history of using eponyms as names of diseases. The 
term Batten disease is still often used, sometimes for CLN3, and sometimes for the 
whole group of NCL diseases. The eponyms previously used for the different forms of 
NCLs are mentioned in chapter 2.3. 
 
2.3 Defective Genes and Proteins 
 
CLN1 / PPT1 
 
Infantile neuronal ceroid lipofuscinosis (CLN1; INCL; Santavuori-Haltia disease; MIM 
256730) is caused by mutations in the CLN1 gene encoding a lysosomal enzyme,  
palmitoyl protein thioesterase 1 (PPT1) (Vesa et al., 1995; Hellsten et al., 1996; 
Verkruyse and Hofmann, 1996). The gene was identified by positional cloning 
strategies after linkage to chromosome 1p32 had been demonstrated (Järvelä, 1991). 
PPT1 removes palmitate groups from proteins in vitro (Camp and Hofmann, 1993; 
Camp et al., 1994). In COS-1 cells PPT1 is targeted to the lysosomes through the 
mannose-6-phosphate pathway. In neurons, however, PPT1 is located in synaptosomes, 
synaptic vesicles and axons (Heinonen et al., 2000a; Lehtovirta et al., 2001; Suopanki 
et al., 2002; Ahtiainen et al., 2003). The PPT1 protein is highly conserved in mammals, 
and the mouse Ppt1 protein shows processing and intracellular localization similar to 
its human counterpart (Salonen et al., 1998). A subtype of CLN1 with juvenile onset, 
but with the typical granular osmiophilic deposits (GROD), is caused by "milder" 
missense mutations on the CLN1 gene (Mitchison et al., 1998). The proteins of the 
storage material in CLN1 consist mainly of sphingolipid activator proteins (SAPs), 
detected only in small amounts in other NCLs (Tyynelä et al., 1993). A second 
enzyme, PPT2, shares 18% amino acid identity with PPT1. Like PPT1, PPT2 is a 
lysosomal thioesterase that hydrolyzes the long-chain fatty acyl coenzyme A, but with 
a substrate specificity that is distinct from that of PPT1 (Soyombo and Hofmann, 
1997). The disruption of either Ppt1 or Ppt2 causes neuronal ceroid lipofuscinosis in 
knockout mice (Gupta et al., 2001). In Finland about 160 patients have been diagnosed, 
compared to about 200 elsewhere (Norio, 2003c). 98% of the Finnish disease 
chromosomes carry the same missense mutation, although 41 different mutations in the 
CLN1 gene has been detected so far. 
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CLN2 / TPP1 
 
Classical late infantile neuronal ceroid lipofuscinosis (CLN2; LINCL; Jansky-
Bielschowsky disease; MIM 204500) is caused by deficiency of a lysosomal serine 
protease, tripeptidyl peptidase I (TPP1) (Sleat et al., 1997; Liu et al., 1998; Sleat et al., 
1999). The defective protein was identified using a mannose 6-phosphate modification 
of newly synthesized lysosomal enzymes as an affinity marker (Sleat et al., 1997). 
When comparing labeled protein samples, a single protein absent in LINCL patients 
was detected. TPP1 cleaves tripeptides from the N-terminus of small peptides 
undergoing lysosomal degradation (Vines and Warburton, 1999). The TPP1 
proenzyme is converted into the mature form of ~48 kDa in the lysosomes (Golabek et 
al., 2002). The pH optimum of the active enzyme is 3.5 (Sohar et al., 1999). The mouse 
Cln2 protein consists of 562 amino acids with 88% identity to its human ortholog 
(Katz et al., 1999a). The nature of the physiological substrates and the range and 
specificity of the enzyme remain unclear.   
 
CLN3  
 
The locus for Juvenile neuronal ceroid lipofuscinosis (CLN3; JNCL; Batten disease; 
Spielmeyer-Vogt-Sjögren disease; MIM 204200) was initially assigned to chromosome 
16 by linkage analyses (Eiberg et al., 1989; Gardiner et al., 1990). The CLN3 gene was 
identified in 1995 and encodes a transmembrane protein, which may have a role in the 
regulation of the vacuolar pH (International Batten Disease Consortium, 1995; Pearce 
et al., 1999). In addition to lysosomes (Järvelä et al., 1998; Golabek et al., 1999), 
several other intracellular localizations have been suggested (Katz et al., 1997; 
Kremmidiotis et al., 1999; Margraf et al., 1999). In the neurons, the protein is 
transported along the neuronal extensions and targeted to neuronal synapses (Järvelä et 
al., 1999; Luiro et al., 2001). Three mouse models of CLN3 have been created, 
showing progressive neurodegeneration and premature death (Katz et al., 1999b; 
Mitchison et al., 1999; Cotman et al., 2002). Interestingly, an autoantibody to glutamic 
acid decarboxylase (GAD65) has been detected in the serum of Cln3 knock-out mice, 
but not in normal mice (Chattopadhyay et al., 2002). The autoantibody to GAD65 was 
also present in the sera of all 20 CLN3 patients studied, in contrast to controls. Thus, 
an autoimmune response to GAD65 is proposed to contribute to a preferential loss of 
GABAergic neurons associated with juvenile neuronal ceroid lipofuscinosis. About 
200 CLN3 patients have been recognized in Finland, but the incidence (1:20.000) is 
almost as high in several other populations (Norio, 2003c). In the CLN3 gene 31 
disease causing mutations have been detected. 
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CLN4  
 
Adult onset forms of neuronal ceroid lipofuscinosis (CLN4; ANCL; Kufs' disease, 
Parry disease; MIM 204300) have been described with both a recessive and a dominant 
pattern of inheritance. Although they represent a heterogeneous spectrum of clinical 
phenotypes and histopathological findings (Berkovic et al., 1988; Nijssen et al., 2003), 
the hypothetical genetic locus of the adult NCL has been named CLN4. Insufficient 
family material and lack of distinct diagnostic criteria has made a genome-wide linkage 
analysis approach difficult. So far, no locus or gene associated with adult NCL has 
been reported. The varying phenotypes might suggest that the adult-onset NCL cases 
are caused by "milder" mutations in the known CLN genes, causing later onset and 
protracted phenotypes, as has already been reported for CLN1 and CLN2. 
Consequently, a specific CLN4 locus may not be found. 
 
CLN5  
 
Finnish variant late infantile neuronal ceroid lipofuscinosis (CLN5, vLINCLFin, MIM 
256731) is described in detail in chapter 3 of the review of the literature as well as in 
the result and discussion parts of this thesis. 
 
CLN6  
 
Variant late infantile neuronal ceroid lipofuscinosis (CLN6; vLINCL; MIM 606725) is 
caused by mutations in a predicted transmembrane protein (Gao et al., 2002; Wheeler 
et al., 2002). Preliminary data suggests localization to the endoplasmic reticulum (Mole 
et al., 2003). The defective CLN6 gene was identified by positional cloning strategies, 
after mapping to chromosome 15q21-23 (Sharp et al., 1997; Sharp et al., 1999; Sharp 
et al., 2001). A total of 16 mutations have been reported and minor differences in the 
pattern of disease symptom evolution were identified (Sharp et al., 2003). In the 
naturally occurring nclf mouse, with an NCL-like phenotype, a 1 bp insertion was 
detected in the orthologous Cln6 gene (Gao et al., 2002; Wheeler et al., 2002). 
 
CLN7  
 
Turkish variant late infantile neuronal ceroid lipofuscinosis (CLN7, Turkish variant 
LINCL) was originally given the locus name CLN7. In some of the Turkish families, 
mutations have recently been detected in the CLN8 gene (Ranta et al., 2003). Whether 
the remaining families represent a novel vLINCL locus, CLN7, or are caused by 
mutations in CLN2, CLN5 or CLN6 remains to be clarified. 
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CLN8 
 
Mutations in the CLN8 gene cause two different clinical phenotypes: Progressive 
epilepsy with mental retardation (EPMR; Northern epilepsy; MIM 600143) and 
Turkish variant late infantile neuronal ceroid lipofuscinosis (former CLN7). The CLN8 
gene was initially linked to chromosome 8 and subsequently identified by sequencing 
the transcripts on the restricted region with DNA of EPMR patients (Tahvanainen et 
al., 1994; Ranta et al., 1999). Recently, mutations in the CLN8 gene have also been 
detected in Turkish families with late infantile NCL (Ranta et al., 2003). The naturally 
occurring motor neuron degeneration (mnd) mouse was observed to harbour mutations 
in the orthologous Cln8 gene (Ranta et al., 1999). CLN8 is an endoplasmic reticulum 
(ER) resident multi-pass transmembrane protein that recycles between ER and the ER-
golgi intermediate compartment (ERGIC) (Lonka et al., 2000). CLN8 has been 
suggested to belong to a novel eukaryotic family of lipid-sensing domains including 
two other ER-resident proteins: the human TRAM and the Saccharomyces cerevisiae 
Lag1 (Winter and Ponting, 2002).   
 
2.4 Animal Models 
 
The identification of the genes underlying the NCL disorders has facilitated the 
development of mouse models of the NCLs (Table 3). Following the cloning of the 
mouse orthologs, mouse models have been produced of CLN1, CLN2, CLN3 and 
CLN5. Also two naturally occurring mouse disorders with NCL-like symptoms and 
pathological findings, nclf and mnd, have been confirmed to be caused by mutations in 
Cln genes. In addition, three other knockout mice with NCL-like phenotypes have been 
characterized (Ppt2, Clcn3 and Ctsd). However, no NCL patient has shown any 
association to the human orthologs of these three genes. 
 
Ppt1 null mutant mice exhibit an NCL-like phenotype with widespread accumulation 
of autofluorescent lipopigments, a shortened lifespan, progressive motor abnormalities 
and spontaneous myoclonic seizures (Gupta et al., 2001). These mice also exhibit 
profound loss of subpopulations of inhibitory interneurons in the cortex and 
hippocampus, with the persisting neurons exhibiting a range of dendritic abnormalities 
and loss of synaptic spines (Cooper, 2003). Based on the findings in the knockout 
mice, Ppt1 appears to play a role in the maintenance of certain neuronal populations 
rather than during their development. Inactivation of Ppt2, another lysosomal 
thioesterase, produces a milder phenotype, suggesting that Ppt2 plays a role in the 
brain not carried out by Ppt1 (Gupta et al., 2001). A new mouse model for Ppt1 has 
been produced, using a knock-in strategy to disrupt exon 4, harbouring the major 
Finnish mutation (unpublished data). These mice showed progressive motor 
abnormalities and died prematurely at the ages of 6-9 months. The pathological 
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findings, includings GRODs and autofluorecent storage materials, are the same as in 
the CLN1 patients.  
 
A mouse model for CLN2 has been produced, and preliminary observations suggest 
that these mice have reduced TPP1 activity in the brain in addition to progressive  
neurological symptoms (Sleat et al., 2003). 
 
Table 3. Mouse models that are orthologous to human NCL types or show pathological 
similarities, such as lysosomal deposition of autofluorescent storage materials and 
neurodegeneration. The exons targeted for mutagenesis using knock-in strategies are marked by 
delta (∆). 
Human gene Mouse model Key references 
CLN1 Ppt1 
Ppt1 (∆ex4) 
Gupta et al., 2001 
Unpublished data 
CLN2 Cln2 Sleat et al., 2003 
CLN3 Cln3 
Cln3 
Cln3 (∆ex7/8) 
Mitchison et al., 1999 
Katz et al., 1999 
Cotman et al., 2002 
CLN5 Cln5 Unpublished data 
CLN6 nclf Bronson et al., 1998 
CLN8 mnd Bronson et al., 1993 
PPT2 Ppt2 Gupta et al., 2001 
CLC-3 Clcn3 Yoshikawa et al., 2002 
Cathepsin D Ctsd Koike et al., 2000 
 
 
Two Cln3 null mutant models have been produced by targeted disruption of the Cln3 
gene (Katz et al., 1999b; Mitchison et al., 1999). Intracellular accumulation of 
autofluorescent material containing subunit C of mitochondrial ATP synthase was 
observed, as in the CLN3 patients. Mutant animals also showed neuropathological 
abnormalities, with loss of certain cortical interneurons and hypertrophy of many 
interneuron populations in the hippocampus (Mitchison et al., 1999). Retinal 
manifestations included accumulation of autofluorescent material and moderate retinal 
degradation, but no significant abnormality was observed in the vision function (Seigel 
et al., 2002).  
 
A third mouse model has been made, using a knock-in strategy to mimic the ~1 kb 
deletion in the CLN3 gene present in the majority of JNCL patients (Cotman et al., 
2002). These Cln3∆ex7/8 mice develop earlier and more pronounced NCL-like 
symptoms than the previous null mutant models, and detectable pathological findings 
are evident even prenatally. As the harmful impact of the mutation on the CNS did not 
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correlate with the membrane deposition, the CLN3 protein activity might be essential 
for the survival of neurons.  
 
The Cln5 knockout mice developed normally and were fertile (unpublished data). 
However, at the age of 3-4 months they developed seizures and their vision started to 
decline. Similarly to the CLN5 patients, the TPP1 activity was significantly increased 
in the brain, kidney and liver of the Cln5-/- mice. At autopsy, the mice showed 
cerebellar atrophy and electron microscopy revealed an ultrastructure with fingerprint 
and curvilinear profiles, analogous to human CLN5 tissues.  
 
Two naturally occurring murine forms of NCL, the mnd (motor neuron degeneration) 
and nclf (neuronal ceroid lipofuscinosis) mice, have been identified on the basis of the 
typical intraneuronal inclusions of autofluorescent material, immunoreactive with 
antibodies to subunit c of mitochondrial ATP synthase (Bronson et al., 1993; Bronson 
et al., 1998). These mice exhibit almost identical phenotypes, with progressive retinal 
atrophy and paralysis at around 9 months of age. Thus it was not surprising that the 
underlying mutations were found in two mouse genes, Cln6 and Cln8, orthologous to 
human genes mutated in two different forms of late-infantile NCL (Gao et al., 2002; 
Wheeler et al., 2002; Ranta et al., 2003). In the mnd (Cln8) mouse, pronounced early 
accumulations of autofluorescent lipopigments has been detected in subpopulations of 
GABAergic neurons, including interneurons in the cortex and hippocampus (Cooper et 
al., 1999). Treatment with insulin-like growth factor-1 partially restored the 
interneuronal number and reduced hypertrophy in some subregions. The mnd mouse 
has been shown to manifest behavioral abnormalities, including increased activity, 
hightened aggression and poor memory, prior to the onset of gross motor symptoms 
(Bolivar et al., 2002). 
 
Cathepsin D deficient mice have been shown to manifest seizures and become blind 
near the terminal stage (Saftig et al., 1995). The Ctsd-/- mice are born normally but die 
on postnatal day 26 ± 1 because of massive intestinal necrosis, thromboembolia, and 
lymphopenia (Koike et al., 2000). Subunit C of the mitochondrial ATP synthase was 
found to accumulate in the lysosomes of neurons, and the activity of TPP1 was 
significantly increased in the brain. These findings suggest that Cathepsin D deficient 
mice show a new form of NCL. Surprisingly, chloride channel-3 (Clcn3) null mutant 
mice also exhibit an aggressive NCL-like phenotype, which closely resembles that of 
Ctsd-/- (Yoshikawa et al., 2002).  Furthermore,  an elevation in the endosomal pH of the 
Clcn3-/- mice was detected. Among other roles, chloride channels act to regulate the 
ionic composition of intracellular compartments and thus their pH (Cooper, 2003). 
Elevated lysosomal pH has been detected in all NCL forms except CLN2 and CLN8 
(Holopainen et al., 2001). Elevated pH most probably disturbs the catalytic activity of 
the lysosomes and is one important factor in explaining the accumulation of the ceroid 
and lipofuscin-like autofluorescent lipopigments characteristic of NCLs.  
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Cathepsin B null mice and Cathepsin L null mice show no obvious pathological 
phenotypes, but mice lacking both Cathepsin B and L manifest severe cerebral and 
cerebellar atrophy leading to death during the second to fourth week of life (Felbor et 
al., 2002). These mice only partly reproduce NCL-like features as the lysosomal 
accumulation material is distinct from the one found in NCL mice.   
 
Experiments with larger animal models could be useful for assaying the biodistribution 
and efficacy of potential therapies, as these become available. Naturally occurring 
sheep strains that show recessive NCL-like disorders are the best characterized 
examples so far. NCL in New Hampshire sheep (OCL6) has been shown to be 
synthenic with the human CLN6 (Jolly and Walkley, 1999). This ovine model has a 
characteristic loss of GABAergic interneurons. A mutation in the ovine cathepsin D 
gene causes severe neurodegeneration and lysosomal storage of granular osmiophilic 
deposits (GROD) containing SAPs A and D, as in CLN1 patients with PPT1 deficiency 
(Tyynelä et al., 2000).  
 
2.5 New Approaches to Characterize Molecular Pathogenesis 
 
To clarify the potential molecular interactions and metabolic pathways of the CLN 
proteins, new genome-wide approaches can be applied to analyse the available animal 
models for NCLs (Brooks et al., 2003). Using oligonucleotide arrays, changes in gene 
expression in the brains of 10-week-old Cln1- and Cln3-knockout mice were detected 
compared to wild-type controls, and partly confirmed by immunoblotting (Elshatory et 
al., 2003). Despite the similarities in pathology, the two mutations affect the expression 
of different, non-overlapping sets of genes. Interestingly, the gene showing the highest 
degree of downregulation in the Cln1-knockout mouse  (mouse EST, GenBank acc. no. 
AI505387) is the most highly up-regulated transcript in the Cln3-knockout. The 
significance of this observation awaits characterization of the function of this novel 
gene. In the Cln3-knockout mice, two genes associated with glutamate utilization were 
downregulated, namely glutamine synthetase and the glutamate receptor mGluR3. This 
might be caused by the presence of the autoantibody to GAD65, which inhibits 
conversion of glutamate to GABA and therefore leads to an accumulation of glutamate 
(Chattopadhyay et al., 2002).     
 
The metabolic profile of cerebral cortex extracts of the mnd (Cln8) mouse has been 
analyzed by high-resolution NMR spectroscopy and principal component analysis 
(Griffin et al., 2002). A profound vitamin E deficiency was detected in both serum and 
brain. Dietary vitamin E supplementation significantly reversed some of the metabolic 
abnormalities, but had no effect upon brain pathology. An interesting finding was the 
increased level of glutamate in combination with decreased GABA in the cerebral 
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cortex tissue. This links the CLN8 protein deficiency with the abnormalities in the 
GABAergic neurons observed in CLN1, CLN3 and ovine CLN6.  
 
In a screen for genes that control synapse development, spinster (spin), which encodes 
a multipass transmembrane protein, has been identified (Sweeney and Davis, 2002). 
The Spin protein has been localized to a late endosomal compartment and Drosophila 
spin mutants showed altered endosomal/lysosomal function and accumulation of ceroid 
lipid pigment and GM2-ganglioside-like substance in the neurons. Synaptic overgrowth 
was detected in the spin mutants, and was shown to be caused by enhanced or 
misregulated TGF-β signaling. The parallel findings in spin mutants and NCLs is 
striking and these findings might provide important information about the connection 
between membrane traffic, lipid organization, synaptic development, growth factor 
signaling, and their defects resulting in neurodegenerative lysosomal storage diseases 
(Sanyal and Ramaswami, 2002). 
 
2.6 Diagnostics 
 
The identification of most of the mutations behind the NCLs has facilitated precise 
molecular diagnosis (Goebel et al., 1999; Mole et al., 2001b). However, more 
traditional methods and skillful clinicians are still needed to identify the cases with 
potential mutations in the CLN genes. When a neurodegenerative disease is suspected, 
the initial tests are MRI and electron microscopy of skin or of a rectal biopsy. If typical 
morphological ultrastructures for NCLs are detected, the next step is enzyme activity 
analysis (PPT and TTP) and DNA analysis. Analysis of the mutation has to be 
designed based on the clinical phenotype in combination with the local frequencies of 
the different NCL types and mutations.  
 
Currently, electron microscopy is still the "gold standard" for determination of whether 
a patient with neurological abnormalities has an NCL disease or not. Based on the 
ultrastructure and clinical picture, the subtype is then predicted and mutation screening 
can start. Identification of the causative mutation is important for determination of the 
exact molecular diagnosis. In addition it allows carrier testing of relatives, and gives 
reliable information about the prognosis. Only in families with previously detected 
NCL mutations, is DNA analysis the primary diagnostic method.  
 
Prenatal diagnosis is possible for families with previous NCL children (Rapola et al., 
1999). Mutation analysis can be performed with DNA extracted from chorionic villus 
samples (CVS) or from cells cultured from amniocentecis samples. Prenatal diagnosis 
gives the parents the option to abort an affected foetus. Another possibility is 
preimplantation diagnosis which, however, is not in routine use for NCL families in 
Finland. Since prenatal diagnosis and mutation screening of the relatives of NCL 
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patients are associated with difficult ethical considerations, appropriate genetic 
counselling is crucial.   
 
2.7 Therapies 
 
At present, no curative treatment for NCLs is available and the therapeutic outlook 
remains bleak. Many ethical and technical challenges also remain to be solved before 
treatment can be offered to patients. With several animal models available, the 
systematic testing of therapeutic interventions is now possible. Replacement of the 
missing enzyme may be an option for CLN1 and CLN2, but the problems of enzyme 
production and delivery need to be overcome. Gene therapy could be an appropriate 
approach, and recent findings suggest that viral-mediated delivery may be feasible for 
CLN2 (Haskell et al., 2003). 
 
A number of neurodegenerative diseases are characterized by oxidative damage. 
Thereby it has been suggested that treatment with antioxidants could delay or halt the 
progression of the NCLs. Long-term antioxidant supplementation with vitamin E and 
sodium selenite has been given to CLN3 patients, but with no significant response 
(Santavuori et al., 1985; Santavuori et al., 1988). Recently, metabolic profile analyses 
have been used to monitor the effect of dietary supplementation with vitamin E in the 
Mnd mouse model (Cln8) (Griffin et al., 2002). Although the vitamin E deficiency was 
reversed in the mutant mice, it had no effect upon brain pathology or the metabolic 
abnormalities caused by the disease. 
 
Hematopoietic stem cell transplantation has been evaluated in three patients with 
CLN1 (Lönnqvist et al., 2001). The effect on the clinical progression of the disease 
was marginal and this treatment is currently not recommended. However, there is hope 
that transplanted neural stem cells may eventually be capable of replacing damaged 
neurons. 
 
Accelerated apoptosis has been suggested to play a role in the neurodegeneration in 
CLN2 and CLN3 (Dhar et al., 2002). The antiapoptotic properties of the CLN3 protein 
were demonstrated on the basis of the growth rate of lymphoblasts homozygous for the 
common CLN3 mutation (Persaud-Sawin et al., 2002). The drug flupirtine blocks 
apoptosis in lymphoblasts of CLN1, CLN2, CLN3, and CLN6 patients, as well as in 
CLN2 and CLN3 deficient neurons (Persaud-Sawin et al., 2002). Therefore flupirtine 
was suggested as a useful drug capable of halting the progression of neurodegenerative 
diseases caused by dysregulated apoptosis. As defects in regulation of apoptosis are 
involved in the development of cancer and as CLN3 is overexpressed in several cancer 
cell lines, CLN3 has been proposed as a molecular target for cancer drug discovery 
(Rylova et al., 2002).  
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As the focus eventually shifts towards testing potential therapies on patients, it will be 
essential that rigorously defined landmarks exists for quantitative measurement of the 
disease progression and evaluation of therapeutic efficacy. Potential indicators for the 
clinical condition include motor, visual and verbal functions, somatosensory evoked 
responses and brain imaging. Although some protocols for follow up have been 
presented for specific forms of NCL, a standardized user friendly scale to score the 
clinical course of NCLs will prove particularly valuable in defining specific endpoints 
in the design of clinical trials (Steinfeld et al., 2002). 
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3. CLN5 (FINNISH VARIANT LATE INFANTILE NCL) 
 
Neuronal ceroid lipofuscinoses (NCL) are inherited lysosomal storage disorders, 
composing the most common type of progressive encephalopathies in children. One of 
the six subtypes of NCL, the Finnish variant form of late infantile neuronal ceroid 
lipofuscinosis (CLN5), was originally described in 1982 (Santavuori et al., 1982). In 
that report, Santavuori presented 16 patients with similar histopathological findings but 
with clinical symptoms slightly different from those seen in the classical form of late 
infantile neuronal ceroid lipofuscinosis (LINCL; CLN2), previously also called Jansky-
Bielschowsky disease. CLN5 later turned out to be a typical exampel of a disease 
belonging to the Finnish Disease Heritage.  
 
The nomenclature and classification of the NCL diseases is complex and has been 
shifting over the years. Different names and abbreviations used for CLN5 are among 
others: vLINCL, fvLINCL, vLINCLFinnish, vLINCLFin, variant CLN2, NCL5, variant 
Jansky-Bielschowsky disease and JBVD. In this thesis, I will use CLN5 as the name 
for the disease, CLN5 for the defective gene, CLN5 for the defective protein, Cln5 for 
the corresponding mouse gene and Cln5 for the mouse protein. 
 
3.1 Clinical Features 
 
In the original series of 16 CLN5 patients, the onset of the disease occurred between 5 
and 7 years of age (Santavuori et al., 1982). The first symptoms were mental 
retardation and visual failure, followed by ataxia, myoclonia and epilepsy. In 1991 a 
series of 5 CLN5 patients was presented, showing that the spectrum of the disease was 
wider than had previously been assumed (Santavuori et al., 1991). The leading 
symptoms in these patients were mental and motor disturbances appearing between 4.5 
and 7 years of age. Visual failure, ataxia, myoclonia and epilepsy developed in all the 
children before the age of 10 years (Figure 3). Independent walking ability was lost 
between 8-11 years. All the patients became blind by ten years of age and gradually 
lost their ability to speak and move, and became spastic and deeply retarded. These 21 
patients have later been shown to be homozygous for the Finnish major mutation in the 
CLN5 gene.The life expectancy for CLN5 patients is about 20 years, with variation 
observed from 14 to 39 years (Norio, 2003c). Sleep disturbances are common in CLN5 
patients, including an excess of nocturnal sleep and frequent daytime naps (Kirveskari 
et al., 2001). 
 
31 
 
Figure 3. A 15-year-old Finnish CLN5 patient (left) together with his sister. 
 
 
3.2 Genetic Background 
 
The effort to clarify the genetic background of the CLN5 disease was initiated at the 
beginning of the 1990s. Carefully performed clinical diagnoses, high-quality 
population records kept by the Finnish Church since the 17th century, and active 
cooperation of the CLN5 families made this step possible. Initially the CLN1 and 
CLN3 loci were excluded for CLN5 by linkage analyses (Järvelä, 1991; Williams et 
al., 1994). Fourteen Finnish CLN5 families, with a total of 67 individuals, including 17 
patients, were used in the linkage studies that resulted in mapping of the CLN5 locus to 
a well-defined region on 13q21.1-q32 (Savukoski et al., 1994). Since one of the disease 
haplotypes ("4.5") generated with markers D13S162 and D13S160, located 3 cM apart, 
was present in 78% of the CLN5 chromosomes, it is likely that one ancient founder 
mutation was introduced into this haplotype and spread in the internal isolate of 
Finland. 
 
To further investigate the origin and age of the founder mutation, genealogical and 
linkage disequilibrium analyses of 18 CLN5 families were performed (Varilo et al., 
1996). Among the 36 parents of the CLN5 patients, 24 (67%) were found to be 
consanguineous with 1-7 other parents. The oldest traced common ancestor originates 
from the 17th century, 13 generations ago. All common ancestors in the large CLN5 
pedigrees lived in five nearby parishes, Kauhajoki, Kauhava, Kuortane, Kurikka, and 
Lapua, which are situated in Southern Ostrobothnia in Western Finland (Figure 4). In 
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this region 12 affected children had been diagnosed during the last 20 years, revealing 
a local incidence of 1/1500. The major CLN5 mutation, homozygous in most Finnish 
patients, obviously occurred some 20-30 generations and 500-750 years ago. The 
combination of the results of the genealogical and linkage disequilibrium studies 
restricted the chromosomal region containing the CLN5 gene from 4 cM (~ 4 Mb) to 
less than 400 kb. 
 
 
 
 
Figure 4. The map on the left shows the birthplaces (dots) of the grandparents of the Finnish 
CLN5 patients. All common ancestors of the CLN5 patients lived in five neighbouring parishes 
in Southern Ostrobothnia: Kauhava, Lapua, Kuortane, Kurikka and Kauhajoki. The pedigree 
shows the relationships between the five families with CLN5. Modified from Varilo et al., 1996 
and Peltonen et al., 1999. 
 
Ancient recombination events detected by isolation of two novel polymorphic markers 
restricted the critical region of the CLN5 locus to 200 kb (Klockars et al., 1996). A 
physical map based on a contig of overlapping PAC clones over the CLN5 region was 
33 
constructed using the Fiber-FISH technique. This made it possible to initiate the last 
phase of the positional cloning of the CLN5 gene, namely the mutation detection of the 
transcripts on the region. Three PAC clones covering the critical 200 kb containing the 
CLN5 locus were sequenced as part of the Human Genome Project at the Whitehead 
Institute for Biomedical Research, USA. Three genes and two pseudogenes were 
identified by cDNA library screenings, EST database searches and using gene 
prediction programs (Klockars et al., 1999). Sequencing of these genes with DNA from 
patients and controls resulted in the detection of three mutations in one of the novel 
genes, which was therefore named CLN5 (Savukoski et al., 1998). Identification of the 
disease causing mutations facilitates reliable prenatal diagnosis, which is now available 
for families with the major Finnish mutation (Rapola et al., 1999). 
 
CLN5 is a glycoprotein predominantly targeted to lysosomes in transiently transfected 
BHK and COS cells. The pathogenesis has been suggested to be associated with 
defective lysosomal trafficking, which prevents the normal biological function of the 
CLN5 protein. (Isosomppi et al., 2002) The CLN5 protein has been reported to interact 
with CLN2 and CLN3, based on results from co-immunoprecipitation and in vitro 
binding assays (Vesa et al., 2002). mRNA and protein expression of CLN5 in the 
embryonic human brain has been characterized by in situ hybridization and 
immunohistochemical staining. Expression was evident in the developing cortex, 
hypothalamus and cerebellum. The most intense signal was detected in the precursors 
of the Purkinje cells of the cerebellum, correlating well with the severe cerebellar 
atrophy seen in the CLN5 patients. (Heinonen et al., 2000b)  
 
3.3 Pathology 
 
Macroscopically severe atrophy of the cerebellum combined with moderate cerebral 
atrophy has been observed in autopsies of CLN5 patients (Figure 5) (Tyynelä et al., 
1997). The patients displayed a uniform and extreme cerebellar atrophy, with almost 
complete destruction of the granule cells and Purkinje cells. Advanced loss of cortical 
neurons was observed, the remaining cells displaying pronounced storage 
enlargements. The hippocampus was relatively spared, and there was extensive cortical 
astrocytosis. Electron microscopy showed that the predominant ultrastructure of the 
intraneuronal storage material was characterized by rectilinear (RL) or atypical 
curvilinear (CL) profiles, with occasional fingerprint bodies (FP). Previous analyses of 
biopsy samples had shown a combination of curvilinear (CL) and fingerprint (FP) 
structure (Santavuori et al., 1982).  
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Figure 5. Whole brain (left) and sagittal section (right) of the brain of a 14-year-old female 
CLN5 patient. The severe atrophy of the cerebellum is the most striking macroscopic 
abnormality. Modfied from Tyynelä et al., 1997. 
 
 
Pathomorphological and biochemical analyses showed that the main protein in the 
storage complexes in the lysosomes of CLN5 brain samples is the subunit c of the 
mitochondrial ATP synthase (Tyynelä et al., 1997). The storage complexes also 
contain minor amounts of sphingolipid activator proteins (SAPs). The 
immunohistological distribution of subunit c and SAPs in the central nervous system 
closely resembles those of classical LINCL. 
 
 
3.4 Brain Imaging 
 
The characteristic electrophysiological findings in CLN5 are posterior spikes in the 
EEG during a low-rate photic stimulation, and giant visual and somatosensory evoked 
potentials (Santavuori et al., 1982). Already at the time of diagnosis, magnetic 
resonance imaging (MRI) and computed tomography (CT) showed generalized brain 
atrophy, which was especially pronounced in the cerebellum (Autti et al., 1992; Autti 
et al., 1994; Autti et al., 1996; Autti et al., 1997). Magnetoencephaography (MEG) of 
CLN5 patients has shown a selective enhancement of the early cortical response to 
median nerve stimulation (Lauronen et al., 2002). This may reflect defective 
interneuronal inhibition in the cortex. 
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AIMS OF THE STUDY 
 
 
 
When this study was initiated the clinical features of the CLN5 patients had been 
described and the autosomal recessive mode of inheritance had been established. The 
locus for CLN5 had been mapped to chromosome 13q22 and the critical region had 
been restricted to less than 200 kilobases.  
 
The initial aim of this study was to identify the CLN5 gene mutated in this disease. 
During the project, the following additional goals were formulated: 
 
- To characterize the novel CLN5 gene and its disease-causing mutations. 
 
- To find out whether there is a correlation between the clinical phenotypes and the 
genotypes of CLN5, caused by different mutations. 
 
- To characterize the orthologous mouse Cln5 gene, and to analyze the expression, 
processing and localization of the Cln5 protein it encodes. 
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MATERIALS AND METHODS 
 
 
Table 4. The materials and methods used in this study are described in detail in the original 
publications (I-III) according to this table. 
Materials and methods Original publication 
Patients I, II 
cDNA cloning I, III 
mRNA analysis by Northern blotting I, III 
PCR and sequencing I, II 
Bioinformatics I, III 
Brain imaging (CT and MRI) II 
mRNA analysis by in situ hybridization III 
Construction of expression plasmids III 
In vitro mutagenesis III 
Cell culture and transfection III 
Protein production by in vitro translation III 
Triton X-114 solubility assay III 
Antibodies III 
Western blotting III 
Metabolic labeling and immunoprecipitation III 
Immunofluorescence III 
Immunohistochemistry III 
 
 
Patients 
 
The 18 CLN5 families, including 21 patients, we used for mutation screening (I) were 
the same as previously used for the linkage analyses (Savukoski et al., 1994; Klockars 
et al., 1996; Varilo et al., 1996). All patients were examined by the same physician and 
the diagnosis was based on the clinical course of the disease, neurophysiological and 
ophtalmological findings, and electron microscopy (EM) studies of biopsies from the 
rectum wall (Santavuori et al., 1982; Santavuori et al., 1991). DNA was extracted from 
frozen periferal blood samples according to standard protocols (Vandenplas et al., 
1984).  
  
The patient group used for genotype-phenotype correlations (II) consisted of six 
Finnish patients, one Dutch patient, and one Swedish patient with CLN5. Mutations in 
the CLN5 gene were found in both alleles of all eight patients. Three were 
homozygous for the Fin major mutation, two were homozygous for the Fin minor 
mutation, one was homozygous for the Dutch mutation and two were compound 
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heterozygotes. Information about the clinical courses of the patients were obtained 
from medical records and from discussions with the clinicians and parents of the 
patients. All patients received drug therapy for epilepsy. 
 
Computed tomography (CT) and Magnet Resonance Imaging (MRI) of the patients 
were performed by experinced radiologists as described previously (Autti et al., 1992; 
Autti et al., 1994; Autti et al., 1996; Autti et al., 1997). Neurophysiological tests were 
done according to normal clinical practice (Santavuori et al., 1982; Santavuori et al., 
1991).  
 
Mutation detection and sequencing 
 
The screening of mutations of positional candidate genes was performed by comparing 
PCR (Saiki et al., 1985; Saiki et al., 1988) amlified genomic DNA from CLN5 patients 
and controls using the manual solid-phase sequencing method (Syvänen et al., 1989). 
The mouse Cln5 gene was characterized by cycle sequencing in accordance with the 
manufacturer's instructions using ABI PRISM BigDye Terminator sequencing kits 
(Perkin Elmer Corporation). The fragments were separated on an Applied Biosystems 
377XL sequencer (Perkin Elmer) and the sequences were interpreted using the 
Sequencing Analysis 3.3 program (Perkin Elmer) and Sequencher 3.0 program (Gene 
Codes Corporation). 
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ETHICAL CONSIDERATIONS 
 
 
Prenatal Diagnosis and Carrier Screening 
 
All the blood and tissue samples used in this study have been collected with informed 
consent according to the World Medical Association’s Declaration of Helsinki 
(http://www.wma.net). The declaration states that it is the duty of the physician in 
medical research to protect the life, health, privacy, and dignity of the human subjects.   
 
As a result of this study, prenatal diagnosis is now available for parents with previous 
CLN5 children. Regarding the severity of this disease, abortion is an understandable 
choice if the foetus is tests positive - at least in Northern European societies. It is 
important to remember that the acceptance of prenatal diagnosis and abortion is greatly 
dependent on the local culture and the ideology and religion of the subjects. A difficult 
question is whether family members and relatives of CLN5 patients should be tested to 
find carriers. The situation is particularly problematic if the recently diagnosed patient 
has got younger, healthy siblings that could be diagnosed presymptomatically. 
Currently DNA tests are available only for the Finnish major CLN5 mutation at the 
laboratory of the Helsinki University Central Hospital.  
 
As the carrier frequency of the Finnish major mutation locally in some communes in 
Southern Ostrobothnia is as high as 1:24-1:44 (Savukoski et al., 1998; Pastinen et al., 
2001), screening of pregnant women for this mutation could be considered. However, 
carrier screening for rare recessive diseases has to be based on voluntariness and 
autonomy, and requires appropriate genetic counselling locally available, which has 
shown to be difficult and expensive to organize (Jallinoja, 2002). So far, no systematic 
carrier screening of any NCL mutation is offered.    
 
Animal Experiments 
 
The use of laboratory animals is a matter of great public concern. In the European 
Union there is a general need and commitment to reduce the number of animals used in 
laboratories for experimental and other scientific purposes to the minimum level that is 
scientifically necessary (EU Commission Communication to the Council and the 
Parliament COM (99)191; http://europa.eu.int/comm/environment/docum/ 
99191_en.pdf).  
 
In this study, rabbits and guinea pigs have been used for raising antibodies, and mouse 
tissues for in situ hybridization and immunohistochemical staining. Animal care and 
handling were consistent with the Guide for the Care and Use of Laboratory Animals 
(National Research Council, 1996)(http://bob.nap.edu/html/labrats/). 
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Criticism of the use of animals in medical research is commonly based on the rights of 
animals: (1) to live without pain, (2) to live in species-specific conditions, and (3) to 
live without having life involuntarily terminated. The first condition is widely accepted 
and efforts are made to minimize the suffering of laboratory animals. The right to live 
in species-specific conditions is not possible to fulfil in laboratories, but much can be 
done to enhance the living conditions of animals. The animals' right to life is more 
controversial. Peter Singers utilitarian theory is based on equal respect for the interests 
of each individual, but according to him the right to life is limited to self-conscious 
animals (Singer, 1975). Tom Regan, on the other hand defends deontological ethics 
and claims that even painless killing of an animal causes massive harm to the animal 
by depriving it of its chance to live (Regan, 1983). This discussion will continue and 
hopefully the principle of the three Rs - reduction, replacement and refinement - will 
prove efficient in reducing the suffering and killing of animals in biomedical research. 
 
Social Impacts of Genetics 
 
Since the beginning of genetic research, its social consequences have been widely 
discussed. This is not surprising, since today's genetics brings detailed information 
about the origin and nature of the human being and about the inherited variations 
between individuals. The responsible use of this new technology is a tremendous 
challenge for scientists and societies.  
 
Can confidentiality always be guaranteed for genetic information about individuals and 
families? May genetic information be used for discrimination in health insurance and 
employment? Should products of genetic information be patented, and by whom - 
individual researchers, universities, funding organizations, private corporations, or the 
indivuals from whom the genetic information was obtained? What are the rights of 
indigenous peoples to their traditional knowledge? Is there a risk for stigmatization of 
patients with genetic diseases? What social consequences will the introduction of 
GMO crops have for the farmers in the South? Most of the ethical questions raised by 
genetics remain unsolved and continuous public discussion on these issues should be 
encouraged.  
 
To meet the public concerns about genetics and medical research, new legislations 
have been introduced, ethical committees have been formed in many hospitals and 
research institutes, and ethical guidelines and recommendations have been developed. 
The National Human Genome Research Institute created the Ethical, Legal, and Social 
Implications (ELSI) Research Program in 1990 as an integral part of the Human 
Genome Project (Collins et al., 2003) (http://www.genome.gov/PolicyEthics/). In 
1997, the General Conference of UNESCO adopted the Universal Declaration on the 
Human Genome and Human Rights, which states that the human genome is a heritage 
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of humanity and that "benefits from advances in biology, genetics and medicine, 
concerning the human genome, shall be made available to all, with due regard for the 
dignity and human rights of each individual". UNESCO's International Declaration on 
Human Genetic Data specifies in more detail the conditions that have to be considered 
in genetic research and genetic testing (http://www.unesco.org/). The European Society 
of Human Genetics has created professional guidelines concerning population 
screening programs, genetic testing for employment and insurances, genetic sevices 
and storage of DNA information (http://www.eshg.org). 
 
The history of eugenics shows how dangerous the misuse of genetic knowledge can be. 
It was hoped that eugenics would "improve" whole populations by preventing certain 
individuals (i.e. disabled, homosexuals, psychiatric patients) from having children, 
while encouraging others. Even in recent years, genetics has been misused as Richard 
Herrnstein and Charles Murray claimed that IQ is largely genetically determined and 
explains social problems such as crime, welfare dependence and single parenting and 
thus programs to eliminate inequalities are doomed to fail (Herrnstein and Murray, 
1994). Their controversial book, the Bell Curve, met an aggressive response i.e. by the 
ELSI working group of the Human Genome Project, arguing that "the lessons of 
genetics are not deterministic and genetic arguments cannot and should not be used to 
determine social policy" (Andrews and Nelkin, 1996).  
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RESULTS AND DISCUSSION 
 
 
 
1. THE HUMAN CLN5 GENE  
 
1.1 Positional Cloning of the CLN5 Gene (I) 
 
When this study was started, the CLN5 locus had recently been mapped to 
chromosome 13 by linkage analysis (Savukoski et al., 1994) and the critical region had 
subsequently been restricted to ~200 kb by linkage disequilibrium (Klockars et al., 
1996). Three PAC clones covering the 200 kb containing the CLN5 locus were 
sequenced as part of the Human Genome Project at the Whitehead Institute for 
Biomedical Research, USA (Figure 6).  
 
 
 
 
Figure 6. Strategy for the identification of the CLN5 gene by positional cloning. 
PAC clones 
Chr 13q22 ~200 kb 
COLAC1 AC224 
Linkage analysis and  
physical mapping 
Transcript identification 
- sequencing of PAC clones 
- EST searches 
- gene predictions 
- cDNA library screening 
Mutation detection 
- sequencing  
3 genes 
2 pseudogenes 
control     ATTACATTACATTAC 
patient     ATTACATTAC - - TAC 
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The complete genomic sequence of the region was essential for identification of the 
genes in the critical region (Klockars et al., 1999). The genomic sequence was used for 
gene predictions with the Genscan (http://genes.mit.edu/GENSCAN/) and MZEF 
(http://argon.cshl.org/genefinder/) softwares. The same sequence was queried against 
human and mouse EST databases using the BLAST algorithm (Altschul et al., 1997). 
In addition, traditional cDNA library screening was performed with the PAC clone 
located between the flanking markers. By these methods, three genes and two 
pseudogenes were identified on the critical CLN5 region. Out of the 24 exons of the 
three genes, 15 were correctly predicted by MZEF, 20 by Genscan, and 21 by human 
EST homologies (Klockars et al., 1999). These three novel genes were sequenced 
using DNA of CLN5 patients, parents and non-related controls. Three mutations were 
initially identified in one of these three genes, which was therefore named the CLN5 
gene.  
 
1.2 Characterization of the Novel CLN5 Gene (I) 
 
The human CLN5 gene spans a genomic region of 13 kb. The full length CLN5 cDNA 
was determined by comparison and fusion of sequences from ESTs, a cDNA clone and 
5'-RACE products. It resulted in a 4.1-kb cDNA sequence, consisting of 4 exons, and 
an open reading frame (ORF) of 1,380 bp. There are four ATG codons in the 5' end of 
the ORF. All of them can be used for translation initiation in vitro (Isosomppi et al., 
2002; Vesa et al., 2002). However, only the fourth one is evolutionarily conserved 
(III), implying an important role for it in humans also. The 407 amino acid polypeptide 
translated from the first potential start methionine was predicted to contain two 
hydrophobic regions with the BCM Transmembrane Prediction Program and the Kyte-
Doolittle hydrophobicity plot. On this basis, the CLN5 protein was considered to be a 
putative transmembrane protein, although no experimental evidence existed at that 
point to support this hypothesis. BLAST searches against the GenBank database did 
not show any homologies for the CLN5 gene with any previously known genes or 
proteins. 
 
The expression pattern of the CLN5 mRNA was analyzed using a 1,291-bp PCR 
fragment to probe a human multiple-tissue Northern blot. Weak signals of 2.0 kb, 3.0 
kb and 4.5 kb were detected in all the tissues. Despite the CNS-specific symptoms, this 
generalized expression is not surprising, since CLN5 patients, like all other NCL 
patients, show lysosomal accumulation of autofluorescent material in non-neural 
tissues also. Ubiquitous expression has also previously been demonstrated for CLN1 
(Camp et al., 1994) and CLN2 (Sleat et al., 1997). However, the pattern of CLN3 
mRNA has some interesting trends. The highest expression level of CLN3 is detected 
in the gastrointestinal tract, and in the glandular/secretory tissue expression is also 
apparently higher than in the CNS (Chattopadhyay and Pearce, 2000). CLN8 
transcripts of three different sizes (1.4, 3.4, and 7.5 kb) can be detected by Northern 
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blotting, showing tissue-specific variation of expression levels (Ranta et al., 1999). 
None of the so far identified CLN proteins show higher expression levels in neural than 
in non-neural tissue. Thus, the CNS-specific symptoms of the patients cannot be 
explained by the expression patterns of the genes. 
     
2. PHENOTYPE-GENOTYPE CORRELATION IN CLN5  
 
2.1 Four Mutations in the CLN5 Gene (I, II) 
 
So far four different mutations have been identified in the CLN5 gene. The most 
common one is the Finnish major mutation, producing a premature stop codon that 
leaves the last 16 amino acids untranslated (Figure 7). This mutation is present in 88% 
(35/40) of the Finnish disease alleles, but has not been found outside Finland. 
Screening of 700 control subjects, originating from a high-risk area on the west coast 
of Finland, revealed a local carrier frequency of 1:24 (10/240) in a population sample 
from one community, where many of the ancestors of the patients have lived. The 
carrier frequency in the rest of the high-risk area was approximately 1:100 (4:460). A 
recent study gave similar results, showing a carrier frequency of 1:44 (9:396) with a 
sample from Kurikka, from Alajärvi and from Lapua, all belonging to the high-risk 
area (Pastinen et al., 2001). A sample from North Karelia in eastern Finland showed 
only one carrier, 1:385, and a sample from Oulu two carriers, 1:183. In a sample of 
1000 people from Helsinki there was only one carrier, 1:1000. These findings correlate 
with the clustering of the ancestors' birthplaces and the linkage disequilibrium interval 
of ~11 cM suggesting that the major Finnish mutation originates from a single person 
who lived in southern Ostrobothnia some 20-30 generations and 500-750 years ago 
(Varilo et al., 1996; Peltonen et al., 1999).   
 
The consequence of the Finnish minor mutation, found in 10% (4/40) of Finnish 
disease alleles, is an early stop codon in exon 1. The patients of one family in Northern 
Finland were homozygous for this mutation. A patient from Sweden was a compound 
heterozygote for this mutation in combination with a novel "Swedish" mutation. The 
missense mutation, found as homozygot only in one Dutch patient changes one 
negatively charged aspartic acid residue at position 279 to a polar but uncharged 
asparagine. The Swedish mutation is an insertion of a cytosine base, causing a 
frameshift leading to 29 wrong amino acids before a premature stop codon at position 
253. This Swedish mutation is found in two compound heterozygotes, one from 
Finland and one from Sweden. Some of the ancestors of this Finnish patient were 
traced to Sweden, so, considering the population history of Finland, it seems likely that 
this rare mutation originates from Sweden. 
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Figure 7. Predicted consequences of the four disease causing mutations on the CLN5 
polypeptide. Modified from II. (Y, tyrosine; W, tryptophane; D, aspartic acid; N, asparagine; H, 
histidine; X, stop)  
 
 
2.2 Clinical Features of Patients with Different Genotypes (II) 
 
Clinical phenotypes of eight patients with different combinations of the four mutations 
were analyzed in detail: three Finnish major homozygotes, two Finnish minor 
homozygotes, the Dutch mutation homozygote, and two compound heterozygotes 
(Swedish + Fin major; Swedish + Fin minor). The detailed clinical data of the study is 
presented in the original publication (Table, II). The age at onset of the disease (2-4 y), 
as well as the ages of the initiation of: mental decline (3-7 y), visual deterioration (5-8 
y), ataxia (7-11 y), epileptic seizures (7-11 y), lost walking ability (8-11 y), abolished 
ERG (6-7 y), and giant fVEP (6-10 y) were assessed. None of these indicators showed 
any clear correlation with any of the genotypes. However, the spectrum of clinical 
development was broad even between patients with identical mutations, with variation 
of 2-4 years in the onset of several signs. 
 
Magnetic resonance images (MRIs) of six of the patients were also analyzed. All the 
patients had enlarged cerebellar sulci, an atrophic vermis, and a dilated IVth ventricle. 
The corpus callosum was abnormally thin in all but one patient. Moderate to severe 
cerebral atrophy was noticed in all three examinations of patients over 9.5 years of age. 
All patients had increased signal intensity of the periventricular white matter and the 
posterior limb of the capsula interna on T2-weighted images. In addition, all the 
patients had abnormally low signal intensity of the thalamus compared to the putamen 
and caudate nuclei at all ages. These results were in line with the previous brain 
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imaging reports of CLN5 patients, emphasizing cerebellar atrophy as the most striking 
structural abnormality (Santavuori et al., 1982; Autti et al., 1992).    
 
2.3 Phenotype-Genotype Correlation in CLN5 (II) 
 
The four CLN5 mutations have very different predicted consequences at the 
polypeptide level (Figure 7). However, no distinct difference was observed in the 
spectrum of symptoms, age of onset or in the speed of progression in the patients with 
different mutations. Thereby it appears likely that each of the four mutations severely 
affects the normal function of the protein, resulting in a functional null allele. 
Expression studies have now shown that the Fin major mutation severely interferes 
with the lysosomal targeting of the CLN5 protein (Isosomppi et al., 2002). It is likely 
that also the Fin minor and Swedish mutations, causing more severely truncated 
polypeptides, result in premature protein degradation, misfolding, or disrupted 
lysosomal targeting. The Dutch mutation changes one negatively charged aspartic acid 
residue to a polar but uncharged asparagines residue. The severity of this missense 
mutation suggests that the mutation affects a functionally or structurally important 
domain of the protein.  
 
In contrast to CLN5, specific mutations causing protracted phenotypes have been 
identified for most of the other NCL disorders (Mole et al., 1999; Mole et al., 2001a). 
In addition to the infantile phenotype, CLN1 mutations might cause late-infantile, 
juvenile and adult onset diseases. CLN2 mutations cause both late-infantile and 
juvenile forms, and a CLN3 mutation with protracted progression of the symptoms has 
been identified. Mutations in the CLN8 gene cause two clearly distinct phenotypes: 
late-infantile NCL and progressive epilepsy with mental retardation. Detailed, updated 
information about all NCL mutations can be found in the NCL Mutation Database 
maintained by Dr. Sara Mole (http://www.ucl.ac.uk/ncl/).  
 
 
3. THE MOUSE Cln5 GENE AND PROTEIN 
 
3.1 Expression and Localization of Cln5 in the Mouse Brain (III) 
 
The mouse Cln5 gene consists of four exons and a coding sequence of 1026 bp, 
translated into a polypeptide of 341 amino acids. An expression construct was made by 
PCR amplification of the coding region from the mouse cDNA IMAGE clone 
#2135359 and insertion of this fragment into the expression vector pcDNA3.1. 
 
The human CLN5 gene was shown to provide transcripts of 2.0 kb, 3.0 kb and 4.5 kb in 
all the tissues studied (I). In the Northern blotting of mouse Cln5 we detected, in all the 
tissues studied (heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis) a 
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major transcript of 2.9 kb and a minor transcript of 2.3 kb (III, Fig. 1 A). Similar to 
human CLN5, some additional bands were seen in the skeletal muscle and lung tissues. 
This may indicate that Cln5 is subjected to tissue-specific alternative splicing or 
polyadenylation signals. The expression level of Cln5 is generally very low. In the 
brain at postnatal day 30 (P30) the steady state transcript level is higher than at P7 and 
embryonal day 13 (E13) (III, Fig. 1 B), suggesting that Cln5 gene expression in the 
brain is under developmental control and increases during brain maturation. Previous 
studies have shown that the expression of Ppt1 and Cln3 are also developmentally 
regulated (Isosomppi et al., 1999; Suopanki et al., 1999a; Suopanki et al., 1999b; 
Ahtiainen et al., 2003). This could indicate that these CLN genes play an important, 
although so far unknown, role in the development and maturation of neurons. 
 
Expression of Cln5 mRNA in the CNS was further studied by non-radioactive in situ 
hybridization. Analyses of embryonic and postnatal mouse brains indicated that Cln5 is 
expressed during early development but also in the mature brain. In agreement with the 
Northern hybridization results, Cln5 gene expression could be detected in several 
developing brain regions as early as embryonic day 15 (E15). At E15, Cln5 mRNA 
was distributed throughout the developing brain, e.g., in the ventricular zone of the 
developing cortical plate, in the ganglionic eminence, and in the hippocampus (III, Fig. 
2).  
 
In the adult mouse brain, Cln5 expression was most intense in the Purkinje cell layer of 
the cerebellum, in the cerebral cortex, as well as in the hippocampal pyramidal cells 
(III, Fig. 2 G-L). The spatial expression pattern provides a striking parallel with the 
CLN5 patients' MRI findings which show severe cerebellar and cerebral atrophy, as 
well as a decreased thalamic signal intensity (Autti et al., 1992). The results from the 
mouse brain are also well in line with our earlier studies of the developing human 
brain, demonstrating Cln5 expression especially in the cerebral cortex, the cerebellar 
Purkinje cells and the thalamic regions (Heinonen et al., 2000b). Interestingly, these 
findings show parallels with the in situ expression pattern reported for Cln1 and Cln3 
(Isosomppi et al., 1999; Luiro et al., 2001). 
 
Immunohistochemical stainings were performed on brain sections from P7 to P60 mice 
(III, Fig. 3 A-I) and the findings were well in line with the Cln5 mRNA distribution 
pattern. Prominent immunostaining was demonstrated in the hippocampal interneurons 
occupying the stratum radiatum,  stratum oriens, and the pyramidal cell layer (III, Fig. 
3 G-I, arrows). Moreover, a specific labeling of CA3 pyramidal cells was found, 
whereas labeling in the CA1 region was much lower. In the large neurons the Cln5 
staining had a granular appearance and was localized predominantly in the cell soma. 
However, some immunostaining could also be seen in the neuronal extensions (III, Fig. 
3 B, D, E). 
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Immunohistochemical stainings corresponded well with the in situ hybridization 
results. Moreover, the Cln5 expression is found in diverse types of neurons, for 
example in the inhibitory Purkinje cells of the cerebellum and in the excitatory mitral 
cells of the olfactory bulb, rather than being restricted to any specific neuronal 
subpopulation. Subcellularly Cln5 localized predominantly to the neuronal cell soma, 
although some weaker immunostaining was also detectable in the neuronal extensions. 
Expression of the Cln5 in the hippocampal interneurons is interesting since earlier 
studies on NCL patients as well as animal models have supplied evidence for 
dysfunction of select inhibitory (GABAergic) circuits, resulting in neuronal loss and 
hypertrophy of the remaining neurons (Williams et al., 1977; Braak and Goebel, 1978; 
Braak and Goebel, 1979; Walkley and March, 1993; March et al., 1995; Cooper et al., 
1999). The expression pattern of Cln5 in the brain and neurons is very similar to that 
reported previously for Cln1 and Cln3, suggesting a shared molecular pathway in 
different NCL disorders (Isosomppi et al., 1999; Luiro et al., 2001; Cotman et al., 
2002).  
 
3.2 Intracellular Targeting of the Mouse Cln5 Protein (III) 
 
The subcellular localization of the mouse Cln5 protein was first studied with confocal 
immunofluorescence microscopy of transiently transfected HeLa and COS-1 cells. 
When cells were fixed with 4% paraformaldehyde followed by permeabilization with 
methanol at -20ºC, the rabbit anti-Cln5 antibody showed a vesicular pattern. In both 
HeLa and COS-1 cells these vesicles overlapped with the lysosomal Lamp1 marker 
H4A3 (III, Fig. 6 A-F). Even some ER-like staining was observed, but disappeared 
after treatment with cycloheximide.  
 
The Finnish major mutation prevents lysosomal targeting of the prematurely 
terminated CLN5 polypeptide, implying that the pathogenesis is associated with 
disturbed intracellular trafficking (Isosomppi et al., 2002). Lysosomal targeting of 
soluble enzymes occurs mainly through the mannose-6-phosphate receptor mediated 
pathway (Rouille et al., 2000) but this has not been verified for CLN5. However, 
further studies are needed to describe the lysosomal targeting mechanism and putative 
enzymatic function of the CLN5 protein. 
 
The intracellular localization was further studied in mouse primary neurons. Since no 
endogenous staining was detected with our antibody, we transfected the neurons with 
mouse Cln5.  In the soma of transfected neuronal cells Cln5 was partially colocalized 
with the lysosomes, although ER-like staining was also observed, as in nonneuronal 
cells (III, Fig. 6 G-J). Interestingly, distinct Cln5 immunostaining was also detected in 
the neuronal extensions corresponding to the Cln5 immunohistochemistry in the brain. 
This staining did not colocalize with the lysosomal marker ID4B, indicating that in 
neurons, Cln5 may have an additional, extralysosomal function.  
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This neuronal staining pattern is not totally surprising, since a similar neuronal 
distribution has previously been demonstrated for PPT1 and CLN3 (Luiro et al., 2001; 
Ahtiainen et al., 2003). This finding may indicate extralysosomal functions in neurons 
for the Cln5 protein. To understand the reason for the CNS specificity of the symptoms 
and the cell degeneration in the patients, the intracellular targeting and the molecular 
interactions of CLN5 in neurons need to be clarified in detail. This will be of great 
interest since previous studies have described the transport of PPT1 and CLN3 into the 
neuronal synapses (Lehtovirta et al., 2001; Luiro et al., 2001; Ahtiainen et al., 2003). 
As CLN2 and CLN3 are potential interaction partners for CLN5 (Vesa et al., 2002), it 
will be interesting to see whether these three proteins follow the same novel 
intracellular transport pathway in neurons.  
 
3.3 Comparison of the CLN5 Proteins of Different Species (I, III) 
 
The CLN5 protein sequences of six different species were compared with each other. 
The human and mouse sequences are publicly available (GenBank accession nos. 
NP_006484 and XP_127882). The coding sequence of the Dictyostelium discoideum 
CLN5 cDNA was obtained from a contig of five EST sequences (AU061512, 
BJ415600, BJ425060, C23678, C91571). The partial polypeptide sequences of pig (Sus 
scrofa; BI182240, BI304716), western clawed frog (Silurana tropicalis; BE468325), 
and channel catfish (Ictalurus punctatus; AL468325) were translated from EST 
sequences. Beginning from amino acid residue 102 of the human CLN5 polypeptide 
(WPVPY...) and reaching to the C-terminus, a striking homology is seen between the 
amino acid sequences of man, mouse, pig, catfish, and frog (Figure 8). The amino acid 
identity between man and mouse in this region is 80%, and the similarity 89%. For all 
the species studied, an N-terminal hydrophobic stretch is observed in the region 
corresponding to the amino acids 75-91 of the human polypeptide. The SignalP v2.0 
program (http://www.cbs.dtu.dk/services/SignalP-2.0/) predicts this region to be a 
signal sequence cleaved by signal peptidase on the lumenal side of the ER membrane. 
BLAST comparisons of the genomic sequences 100 kb upstream of the human CLN5 
and mouse Cln5 genes did not reveal any homologous promotor regions. 
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                          hydrophobic region       cleavage sites 
                          ================ pdh c m         
Human   62  MRRGAGAARGRASWCWALALLWLAVVPGWSRVSGIPSRRHWPVPYKRFDFRP 
Pig            GARAXLGRAPWNWGTALLWLVAAVAATAGS--RSLRQWPVPYKRFSFRP 
Mouse            MLRGGPCGAHWRPALALALLGLATILGASPTSGQRWPVPYKRFSFRP 
Catfish              MGGHWRQGLRSVLLLSIACVSLHSSNGFLQKWPVPYKRFEFRP 
Frog                    MTVKCFYFLFLICLLVLISSQNISGKRVWPVPYRRFDRRP 
Dicty                    MKRTIIILLFVSLFVTFVLS--------QIPDNDPELCQ 
 
Figure 8. Comparison of the N-terminal CLN5 polypeptide sequences of six species. This 
sequence begins with the fourth potential start methionine of the human CLN5 peptide, located 
62 amino acids downstream from the first one. The hydrophobic region, typically observed in 
signal pepties is marked by equal signs (=). The predicted signal peptide cleavage sites are 
marked by h (human), p (pig and frog), m (mouse), c (catfish) and d (dictyostelium). Black 
background indicates identical amino acid and grey background similar amino acid. Modified 
from III. 
 
 
To analyze experimentally whether the N-terminal hydrophobic region of mouse Cln5 
can act as a signal sequence, we compared the sizes of in vitro translated Cln5 and 
deglycosylated Cln5 protein produced in COS-1 cells. Western analysis revealed that 
the apparent size of the deglycosylated Cln5 protein was 34 kDa, while the in vitro 
translation produced a band of 37 kDa (III, Fig. 5B). This would imply that mouse 
Cln5 undergoes signal sequence cleavage resulting in the removal of an approximately 
3 kDa peptide.  
 
To monitor the biosynthesis of the Cln5 protein, we transfected COS-1 cells with the 
mouse Cln5 cDNA construct. The crude cell lysates were deglycosylated with Endo H 
or PNGase F to remove the high mannose oligosaccharides or all N-linked 
oligosaccharides. Western blot analysis revealed two bands of 48 and 50 kDa from the 
Cln5 transfected cells. Treatment with Endo H produced one band of 35 kDa, and 
PNGase F treatment resulted in a 34 kDa band (III, Fig. 5C). Our results suggest that 
mouse Cln5 is a glycoprotein with high mannose-type sugars and additional complex-
type sugars. 
  
The human CLN5 cDNA sequence has four in-frame AUG codons, previously shown 
to encode the polypeptides of 407, 378, 358 and 346 amino acids (Isosomppi et al., 
2002). Only the fourth AUG is conserved in the other species (Figure 8). To analyze 
the significance of the fourth methionine for translation initiation, we transfected COS-
1 cells with the complete human CLN5 cDNA, and a cDNA with the first three 
potential start methionines inactivated (CLN5met4 construct). The CLN5 and 
CLN5met4 constructs showed bands of identical size before and after deglycosylation 
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(III, Fig. 5B). This confirms that the fourth methionine of human CLN5 can alone act 
as a translation initiator.  
 
Table 5 shows the properties of the human CLN5 proteins translated from the first and 
fourth methionines (met1 and met4), compared to the mouse Cln5 protein. The 
similarities between the human CLN5met4 and the mouse Cln5 are striking. The 
lengths of the polypeptides, the molecular weights, and the glycosylation pattern are 
very similar, and both are predicted to undergo signal peptide cleavage, in contrast to 
CLN5met1. This would imply that the human CLN5 protein translated from the fourth 
methionine is carrying out the same function as the Cln5 protein in the mouse, and in 
all other species with identified CLN5 proteins. The use of downstream AUG codons 
for translation initiation is actually more common than is generally believed. A recent 
study shows that more than 40% of transcripts contain AUG codons upstream of the 
actual start codon (Peri and Pandey, 2001). The authors of that work suggest that for 
the purpose of identification of translation start sites from cDNA sequences, it is better 
to use homology-based alignments across species or across protein families, instead of 
relying solely on the most upstream AUG and its context. 
 
 
Table 5. This table shows the basic features of the human CLN5 proteins translated from the 
first and fourth methionines (met1 and met4), compared to the mouse Cln5 protein. The 407 
amino acid polypeptide translated from met1 is not predicted to undergo signal peptide (sp) 
cleavage. *The values indicated with a star are from Vesa et al., 2002.  
 CLN5met1 CLN5met4 Mouse Cln5 
Coding sequence (base pairs) 1224  1041 1026  
Amino acids 407  346 341 
Amino acids after sp cleavage - 312 308 
Molecular Weight (MW) 47* 50-60 50 
Molecular Weight - Endo H 47* 38 35 
Molecular Weight - PNGase F 47* 37 34 
In vitro translation 47* 40 37 
Predicted MW before sp-cleavage 46.3 40.3 39.1 
Predicted MW after sp-cleavage - 36.6 36.1 
GenBank acc. no. (genomic) NT_024524 NT_024524 NT_039609 
GenBank acc. no. (mRNA) NM_006493 NM_006493 XM_127882 
GenBank acc. no. (protein) NP_006484 NP_006484 XP_127882 
 
 
However, the first initiation methionine of CLN5 has been shown to be capable of 
translation initiation in vitro (Isosomppi et al., 2002; Vesa et al., 2002). Using an N-
terminal antibody (raised against amino acids 1-75), a 47-kDa band was detected in 
Western blotting (Vesa et al., 2002). Moreover, this protein was shown to be 
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membrane bound and to lack any N-linked glycans. This 47-kDa isoform can be 
produced in vitro in transient cDNA expression systems, but whether it also has a role 
in vivo remains to be clarified.    
 
The 5' end of the human CLN5 gene was cloned by 5'RACE and so far no EST 
covering the first AUG codon has been published. This could indicate that the mRNA 
including that codon is an alternatively spliced variant, with tissue-specific or 
developmentally regulated expression. The fact that the 5' end of the coding sequence 
is not conserved in the mouse genome supports this hypothesis. Analyses of 9,434 
orthologous genes in human and mouse have shown that exons that are only included 
in alternative splice forms are mostly not conserved and thus are products of recent 
exon creation (Modrek and Lee, 2003). As the total numbers of genes in human and 
mouse are almost identical, it seems likely that much of the recent evolutionary 
changes causing the differences between mammals are caused by alternative splicing. 
Thus, it is possible that human CLN5 encodes two different proteins, although mouse 
Cln5 encodes only one.     
 
3.4 Is CLN5 a Transmembrane or a Soluble Protein? (I, III) 
 
In publication I we speculated that CLN5 could be a transmembrane protein. This was 
based on computational analysis of the 407 amino acid polypeptide, as we assumed 
that the first AUG is the initiator of translation. This prediction was made using the 
TMpred transmembrane prediction program and Kyte-Doolittle hydrophobicity plot. 
However, the ability of these programs to distinguish between soluble and 
membranous proteins is poor (Moller et al., 2001). Currently the best performing 
programs are TMHMM (http://www.cbs.dtu.dk/services/TMHMM/)(Krogh et al., 
2001) and SOSUI (http://www.tuat.ac.jp/mitaku/sosui/)(Hirokawa et al., 1998). Neither 
of them predicts any transmembrane regions for CLN5 in any species. The stronger of 
the two hydrophobic regions predicted, has been shown to belong to the signal 
sequence of the CLN5 polypeptide translated from methionine 4 (III). 
 
To further pursue whether mouse Cln5 represents a membrane-bound or a soluble 
protein, Triton X-114 phase separation was performed. With this method soluble 
proteins are found exclusively in the aqueous phase, and membrane proteins recovered 
in the detergent phase (Bordier, 1981). Transfected COS-1 cells were lysed with Triton 
X-114 buffer, condensated, centrifuged, and the two phases were then separated and 
analyzed by Western blotting using the guinea pig anti-Cln5 antibody. Mouse Cln5 and 
also the 312 amino acid human CLN5 protein analyzed in parallel experiments were 
found exclusively in the aqueous phase (Figure 9). Protein Disulphide-Isomerase 
(PDI), which is a soluble protein of the endoplasmic reticulum, was endogenously 
detected from the Cln5 transfected cells. It was recovered exclusively in the aqueous 
phase. The human transferrin receptor, which is a type II transmembrane protein with a 
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single 28 residue transmembrane region, was found predominantly in the detergent 
phase of the lysate of Cln5 transfected cells. 
 
Figure 9. Triton X-114 phase separation of transfected COS-1 cells. The crude lysate, the 
aqueous phase and the detergent phase were analyzed by Western blotting. Modified from III.  
 
 
 
These results clearly indicate that the CLN5 proteins of human and mouse, after signal 
peptide cleavage, are soluble proteins. Howerver, the 407 amino acid polypeptide 
translated from the first AUG codon has been detected from the detergent phase after 
Triton X-114 phase separation (Vesa et al., 2002). The location and function of this 
putative transmembrane isoform, possibly encoded by an alternatively spliced mRNA, 
remains elusive. 
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Figure 10. Schematic picture of the intracellular localization of the CLN proteins. Cathepsin D 
(CTSD) and Chloride channel-3 (CLC-3) deficient mice manifest NCL-like symptoms and 
lysosomal accumulation. 
 
 
 
Among the six CLN proteins, PPT1, TPP1 and CLN5 have now been shown to 
represent soluble lysosomal proteins (Figure 10). CLN3 is a lysosomal membrane 
protein, and CLN6 and CLN8 are predicted membrane proteins localized to the 
endoplasmic reticulum (ER). Cathepsin D is a lysosomal enzyme, deficiency of which 
causes NCL in sheep and mouse (Koike et al., 2000; Tyynelä et al., 2000). Chloride 
channel-3 deficient mice also manifest NCL-like symptoms, which have been 
suggested to be associated with defective endosomal pH regulation (Yoshikawa et al., 
2002). This implies that dysfunction of the ER-golgi-endosome-lysosome biosynthetic-
secretory pathway might be essential for the molecular pathogenesis on the NCLs. 
However, extra-lysosomal localization has also been suggested for PPT1, CLN3 and 
CLN5 in neurons. The potential synaptic functions and intraneuronal targeting 
mechanisms of all the CLN proteins need to be clarified to better understand the 
pathogenesis of the corresponding NCL diseases. 
plasma membrane 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
 
The neuronal ceroid lipofuscinoses (NCLs) are globally the most important cause of 
childhood neurodegeneration. The clinical course is characterized by mental, motor 
and visual decline, further complicated by seizures. Utilizing the recent development of 
molecular genetics, six defective genes have been identified behind these diseases. The 
hallmark of the pathology is the accumulation of ceroid and lipofuscin resembling 
autofluorescent material in the lysosomes of both neuronal and non-neuronal cells. 
However, the molecular cascade and the reasons for the CNS specificity of the 
symptoms and for cell death are not understood. The NCL proteins can be roughly 
divided into two groups, lysosomal enzymes (PPT1, TPP1, Cathepsin D and CLN5) 
and membrane proteins (CLN3, CLN6 and CLN8). Currently, mouse models of all 
NCL diseases are available and will provide a useful tool for further studies of the 
pathological mechanisms and ultimately for therapeutic trials. 
 
In this study we have identified the CLN5 gene by positional cloning strategies. Four 
different mutations were detected in CLN5 patients, but, despite detailed analysis of 
the clinical development, we could not recognize any correlation between the 
phenotypes and the genotypes. To find out more about the general properties of the 
CLN5 proteins in different species, we characterized the mouse Cln5 gene and showed 
that it encodes a soluble lysosomal glycoprotein, expressed throughout the developing 
and mature brain. We also demonstrated that mouse Cln5 undergoes signal peptide 
cleavage and closely resembles the human CLN5 protein translated from the fourth 
potential AUG codon.  
 
So far, the reason for the neuron-specific cell degeneration seen in all NCL patients is 
not understood. Suggested explanations for the neuron-specific effects have been 
many: neurons may be more vulnerable to the storage materials, there might be neuron-
specific substrates for the NCL enzymes, or neuron-specific metabolic pathways could 
be used for all NCL-proteins. Our results with Cln5 as well as previous studies with 
Cln1 and Cln3 suggest that these proteins might have an extra-lysosomal function in 
neurons, not observed in other cells. Further studies are needed to explain the potential 
synaptic function and the intracellular targeting mechanisms of CLN proteins in 
neurons.  
 
An interesting finding is that most of the NCL disorders seem to be linked to 
dysfunction of inhibitory GABAergic hippocampal interneurons. In the serum of 
CLN3 patients and mice, an autoantibody to glutamic acid decarboxylase (GAD65) has 
been detected, which inhibits conversion of glutamate to GABA and so leads to an 
accumulation of glutamate (Chattopadhyay et al., 2002). Degeneration of interneurons 
has been shown in Ppt1 mice (Cooper, 2003), Cln3 mice (Mitchison et al., 1999), mnd 
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(Cln8) mice (Cooper et al., 1999), and ovine CLN6 (Jolly and Walkley, 1999). The 
mnd (Cln8) mice show increased levels of glutamate in combination with decreased 
GABA in the cerebral cortex tissue. (Elshatory et al., 2003) Microarray studies have 
suggested downregulation in the Cln3 mice of two genes associated with glutamate 
utilization, namely glutamine synthetase and glutamate receptor mGluR3 (Griffin et 
al., 2002). Thus our prominent immunohistochemical staining of Cln5 in the 
hippocampal interneurons might be an important finding.   
 
At present, very little quantitative data is available about which cellular populations are 
affected in NCLs and how the sequence of neurodegenerative events subsequently 
develops and ultimately leads to cell death. Discovery of the precise nature and order 
of these events will be crucial for understanding the neurobiology and the therapeutic 
opportunities for these devastating diseases. The mouse models will be useful in future 
studies on the mechanisms leading to cell death, and especially on the potential 
involvement of apoptosis. The role of the accumulation material in the lysosomes is 
still an essential question. Is it the primary cause of neuronal cell death, or just a 
secondary finding relating to the lost protein activity? 
 
New approaches will be essential for analysing the animal models of NCLs, including 
microarrays for monitoring detailed mRNA expression profiles in different tissues and 
developmental stages. Identification of downstream genes involved in the same 
metabolic pathways as the NCL-proteins, would be important. Microarrays could also 
give new clues about the role of genes related to the metabolism of glutamate in the 
pathogenesis of different NCLs. 
 
Comparative proteomics will provide a means for examining the genetic and 
environmental effects on protein expression in control and NCL mice. The role of 
potential molecular interactions between NCL proteins and emerged candidate proteins 
needs to be characterized to find out whether the NCL proteins are involved in a 
common metabolic pathway.  
 
More generally, characterization of the molecular pathogenesis of the NCLs could give 
new insights into the mechanisms involved in neurodegeneration, neuron-specific 
apoptosis, brain development and survival of neurons. Despite the progress followed 
by the identification of the defective NCL genes, successful treatments for these fatal 
disorders remain a distant prospect. Accurate and reliable diagnostic methods, 
including prenatal and carrier diagnostics, and genetic counselling are the clinical 
benefits achieved so far. 
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Internet addresses for databases, programs and organizations mentioned in the text are 
provided below. 
 
 
 
 
 
 
  World Wide Web Site   URL 
Batten Disease Support & Research Association http://www.bdsra.org/ 
BCM Search Launcher  http://searchlauncher.bcm.tmc.edu/ 
Bioinformatics@KTL http://www.ktl.fi/bioinfo/ 
BLAST at NCBI http://www.ncbi.nlm.nih.gov/BLAST/ 
CBS Prediction Servers http://www.cbs.dtu.dk/services/ 
EMBnet http://www.ch.embnet.org/ 
Ensembl http://www.ensembl.org/ 
ExPASy http://us.expasy.org/ 
GENSCAN Web Sever at MIT http://genes.mit.edu/GENSCAN/ 
Guide for the Care and Use of Laboratory Animals http://bob.nap.edu/html/labrats/ 
Human Genome Organisation (HUGO) http://www.hugo-international.org/ 
Human Genome Project Information http://doegenomes.org/ 
I.M.A.G.E. Consortium http://image.llnl.gov/ 
Mouse Genome Informatics http://www.informatics.jax.org/ 
MZEF Gene Finder http://argon.cshl.org/genefinder/ 
National Center for Biotechnology Information  http://www.ncbi.nlm.nih.gov/ 
National Human Genome Research Institute http://www.genome.gov/ 
NCL Mutation Database http://www.ucl.ac.uk/ncl/ 
Online Mendelian Inheritance in Man http://www.ncbi.nlm.nih.gov/Omim/ 
Policy&Ethics http://www.genome.gov/PolicyEthics/ 
Swiss-Prot http://www.ebi.ac.uk/swissprot/ 
The Institute for Genomic Research http://www.tigr.org/ 
UCSC Genome Browser http://genome.ucsc.edu/ 
UNESCO http://www.unesco.org/ 
World Medical Association http://www.wma.net/ 
 
 
57 
ACKNOWLEDGEMENTS 
 
 
This study was carried out at the Department of Molecular Medicine of the National 
Public Health Institute, Helsinki. The former head of the institute, Jussi Huttunen, and 
the new director, Pekka Puska, are acknowledged for providing excellent research 
facilities. The study was financially supported by Finska Läkaresällskapet, Suomen 
Lääketieteen Säätiö, Perkléns minnesfond, and the Helsinki Biomedical Graduate 
School. 
 
For almost eight years I have had the privilege to be supervised by Leena Peltonen-
Palotie. I am grateful for the opportunity to work in such a challenging, competitive, 
and creative environment. Anu Jalanko has been very helpful as co-supervisor and has 
always been available for guidance. I want to thank Outi Kopra for skilful assistance 
and practical help, especially regarding the manuscript of the last publication. I am 
grateful to Irma Järvelä for taking the initiative to the phenotype-genotype correlation 
work.  
 
I want to thank Pirkko Santavuori for introducing me to the clinical viewpoint of the 
NCL-diseases. The opportunity to cooperate with an experienced clinician and the 
chance to meet some of the CLN5 patients and their parents has been invaluable. I 
want to thank all CLN5 patients, their families, and their clinicians for everything they 
have done to contribute to this project. Without their friendly and patient cooperation 
this study would not have been possible. I am particularly grateful to our collaborators 
Paul Uvebrant and Irene Hofman. Leena Lauronen and Taina Autti are acknowledged 
for excellent radiological expertise. Anna-Liisa Fabritius performed the 
immunohistochemical stainings for the last publication and Satu Kuure helped us with 
the in situ hybridizations. I am grateful to Jouni Vesa for providing us with cDNA 
constructs and Cln5-specific antibodies. Tuula Manninen is acknowledged for 
excellent technical assistance. 
 
I wish to express my sincere gratitude to Helena Kääriäinen and Kari Majamaa for 
reviewing this thesis. Their comments and constructive criticism were important for 
improving the manuscript. Hannu Sariola is thanked for participating in my thesis 
committee. Jean Margaret Perttunen is acknowledged for revising the language of this 
thesis. I want to thank our secretaries, Sari Kivikko, Sari Mustala, Tuija Svahnbäck, 
and Helena Knuuttila for friendly assistance. Teemu Perheentupa, Juri Ahokas, Jari 
Raikko, and Martti Sariola have been of great help with a myriad of computer 
problems. 
 
I will never forget the wonderful atmosphere of our CLN5 team. I want to thank 
Tuomas Klockars for introducing me to the field of genetics, for teaching me all the 
58 
basic methods, and for creating a relaxed and positive spirit in the lab. The discussions 
with Minna Savukoski about genetics and medicine have really taught me a lot. Juha 
Isosomppi has been invaluable in giving practical hints about different methods and 
thorough explanations about their theoretical backgrounds. Our hour-long discussions 
about the deepest essence of the CLN5 protein have been both fun and scientifically 
challenging. 
 
For making the everyday-life in the lab most enjoyable I want to thank my present and 
former room mates Heidi, Elina, Aimee, Kaisu N, Henna, and Anna. For great 
company during the years I want to thank Joni, Jenny, Pekka, Tero H, Tintti, Will, Jani, 
Kai, Maria, Gilberto, Tanja, Taina, Nora, Laura, Kaisu L, Nina, Paula, Tarja, Anniina, 
Kristiina, Annika, Mira, Outi, Jenni, Emma, Ilona, Nabil, Mikko, Tero Y, Markus, 
Marjo, Tiina, Teppo,  and Iski.  
 
The countless coffee breaks with Jesper, flavoured with philosophical discussions 
about science, politics and life, created a friendship that helped me to survive even the 
toughest phases of this project. I have had the pleasure to spend the greater part of my 
time in the lab, as well as the first steps in the clinics, together with Niklas, mainly 
discussing tennis. Juha P has provided good humour lab bench company and shown a 
very sound attitude towards science. I want to thank Anil for nice company and many 
interesting reflections on neurology, cardiology, and fig alpha. Since the first moments 
in the Graduate School, Jonas has been an important friend for sharing the frustration 
about all madness in biomedical research and clinical medicine. PKU is also 
acknowledged. 
 
I want to thank all my friends who have helped to keep my mind away from genetics. 
Especially all discussions with Marcus, Hamppe, Samuel, and Mika have been very 
therapeutic. 
 
I also wish to thank all my cousins and their families for all joyful moments together. I 
am grateful to may aunt Britt, for her true caring and helpfulness. My grandparents, 
Ulla and Helge, have always been encouraging and shown great interest in my medical 
and scientific activities. My wonderful sisters, Maya and Hanna, are marvellous 
company for relaxing, chatting and enjoying life. I want to express my warmest thanks 
to my parents, Andrea and Kenneth, for awakening my interest for science and for 
teaching me to question prevailing truths. Your everlasting support and encouragement 
has been invaluable. 
 
Most of all I want to thank Johanna for sharing her life with me. Your love and support 
mean everything to me.  
Ville Holmberg 
Helsinki, February 2004 
59 
REFERENCES 
 
 
Adams, MD, Celniker, SE, Holt, RA, Evans, CA, Gocayne, JD, Amanatides, PG, Scherer, SE, Li, PW, 
Hoskins, RA, Galle, RF, George, RA, Lewis, SE, Richards, S, Ashburner, M, Henderson, SN, 
Sutton, GG, Wortman, JR, Yandell, MD, Zhang, Q, Chen, LX, Brandon, RC, Rogers, YH, 
Blazej, RG, Champe, M, Pfeiffer, BD, Wan, KH, Doyle, C, Baxter, EG, Helt, G, Nelson, CR, et 
al. (2000) The genome sequence of Drosophila melanogaster. Science 287:2185-2195. 
Ahtiainen, L, Van Diggelen, OP, Jalanko, A and Kopra, O. (2003) Palmitoyl protein thioesterase 1 is 
targeted to the axons in neurons. J Comp Neurol 455:368-377. 
Altschul, SF, Madden, TL, Schaffer, AA, Zhang, J, Zhang, Z, Miller, W and Lipman, DJ. (1997) Gapped 
BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids 
Res 25:3389-3402. 
Andrews, LB and Nelkin, D. (1996) The bell curve: a statement. Science 271:13-14. 
Autti, T, Raininko, R, Launes, J, Nuutila, A and Santavuori, P. (1992) Jansky-Bielschowsky variant 
disease: CT, MRI, and SPECT findings. Pediatric Neurology 8:121-126. 
Autti, T, Raininko, R, Vanhanen, SL, Kallio, M and Santavuori, P. (1994) MRI of the normal brain from 
early childhood to middle age. I. Appearances on T2- and proton density-weighted images and 
occurrence of incidental high-signal foci. Neuroradiology 36:644-648. 
Autti, T, Raininko, R, Vanhanen, SL and Santavuori, P. (1996) MRI of neuronal ceroid lipofuscinosis. I. 
Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis. Neuroradiology 38:476-
482. 
Autti, T, Raininko, R, Santavuori, P, Vanhanen, SL, Poutanen, VP and Haltia, M. (1997) MRI of neuronal 
ceroid lipofuscinosis. II. Postmortem MRI and histopathological study of the brain in 16 cases of 
neuronal ceroid lipofuscinosis of juvenile or late infantile type. Neuroradiology 39:371-377. 
Avery, OT, MacLead, CM and McCarty, M. (1944) Studies of the chemical nature of the substance 
inducing transformation of pneumococcal types. Induction of transformation by a 
desoxyribonucleic acid fraction isolated from Pneumococcus Type III. J Exp Med 79:137-158. 
Batten, FE. (1903) Cerebral degeneration with symmetrical changes in the maculae in two members of a 
family. Trans Ophtalmol Soc UK 23:386-390. 
Berkovic, SF, Carpenter, S, Andermann, F, Andermann, E and Wolfe, LS. (1988) Kufs' disease: a critical 
reappraisal. Brain 111:27-62. 
Bielschowsky, M. (1913) Über spät-infantile familiäre amaurotische idiotie mit Kleinhirnsymptomen. 
Dtsch Z Nervenheilk 50:7-29. 
Bolivar, VJ, Scott Ganus, J and Messer, A. (2002) The development of behavioral abnormalities in the 
motor neuron degeneration (mnd) mouse. Brain Res 937:74-82. 
Bordier, C. (1981) Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 
256:1604-1607. 
Braak, H and Goebel, HH. (1978) Loss of pigment-laden stellate cells: a severe alteration of the isocortex 
in juvenile neuronal ceroid-lipofuscinosis. Acta Neuropathol (Berl) 42:53-57. 
Braak, H and Goebel, HH. (1979) Pigmentoarchitectonic pathology of the isocortex in juvenile neuronal 
ceroid-lipofuscinosis: axonal enlargements in layer IIIab and cell loss in layer V. Acta 
Neuropathol (Berl) 46:79-83. 
Bronson, RT, Lake, BD, Cook, S, Taylor, S and Davisson, MT. (1993) Motor neuron degeneration of mice 
is a model of neuronal ceroid lipofuscinosis (Batten's disease). Ann Neurol 33:381-385. 
Bronson, RT, Donahue, LR, Johnson, KR, Tanner, A, Lane, PW and Faust, JR. (1998) Neuronal ceroid 
lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am J Med Genet 
77:289-297. 
60 
Brooks, AI, Chattopadhyay, S, Mitchison, HM, Nussbaum, RL and Pearce, DA. (2003) Functional 
categorization of gene expression changes in the cerebellum of a Cln3-knockout mouse model 
for Batten disease. Mol Genet Metab 78:17-30. 
Camp, LA and Hofmann, SL. (1993) Purification and properties of a palmitoyl-protein thioesterase that 
cleaves palmitate from H-Ras. J Biol Chem 268:22566-22574. 
Camp, LA, Verkruyse, LA, Afendis, SJ, Slaughter, CA and Hofmann, SL. (1994) Molecular cloning and 
expression of palmitoyl-protein thioesterase. J Biol Chem 269:23212-23219. 
Chattopadhyay, S and Pearce, DA. (2000) Neural and extraneural expression of the neuronal ceroid 
lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3. Mol Genet 
Metab 71:207-211. 
Chattopadhyay, S, Ito, M, Cooper, JD, Brooks, AI, Curran, TM, Powers, JM and Pearce, DA. (2002) An 
autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten 
disease. Hum Mol Genet 11:1421-1431. 
Cohen, SN, Chang, AC, Boyer, HW and Helling, RB. (1973) Construction of biologically functional 
bacterial plasmids in vitro. Proc Natl Acad Sci U S A 70:3240-3244. 
Collins, FS, Green, ED, Guttmacher, AE and Guyer, MS. (2003) A vision for the future of genomics 
research. Nature 422:835-847. 
Cooper, JD, Messer, A, Feng, AK, Chua-Couzens, J and Mobley, WC. (1999) Apparent loss and 
hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for 
partial response to insulin-like growth factor-1 treatment. J Neurosci 19:2556-2567. 
Cooper, JD. (2003) Progress towards understanding the neurobiology of Batten disease or neuronal ceroid 
lipofuscinosis. Curr Opin Neurol 16:121-128. 
Cotman, SL, Vrbanac, V, Lebel, LA, Lee, RL, Johnson, KA, Donahue, LR, Teed, AM, Antonellis, K, 
Bronson, RT, Lerner, TJ and MacDonald, ME. (2002) Cln3(Deltaex7/8) knock-in mice with the 
common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum 
Mol Genet 11:2709-2721. 
Darwin, C. (1859) On the origin of species by means of natural selection. John Murray, London.  
de la Chapelle, A. (1993) Disease gene mapping in isolated human populations: the example of Finland. J 
Med Genet 30:857-865. 
Dhar, S, Bitting, RL, Rylova, SN, Jansen, PJ, Lockhart, E, Koeberl, DD, Amalfitano, A and Boustany, 
RM. (2002) Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic 
CLN3- and CLN2-deficient neurons. Ann Neurol 51:448-466. 
Eiberg, H, Gardiner, RM and Mohr, J. (1989) Batten disease (Spielmeyer-Sjogren disease) and 
haptoglobins (HP): indication of linkage and assignment to chr. 16. Clin Genet 36:217-218. 
Elshatory, Y, Brooks, AI, Chattopadhyay, S, Curran, TM, Gupta, P, Ramalingam, V, Hofmann, SL and 
Pearce, DA. (2003) Early changes in gene expression in two models of Batten disease. FEBS 
Lett 538:207-212. 
Felbor, U, Kessler, B, Mothes, W, Goebel, HH, Ploegh, HL, Bronson, RT and Olsen, BR. (2002) Neuronal 
loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A 99:7883-
7888. 
Fleischmann, RD, Adams, MD, White, O, Clayton, RA, Kirkness, EF, Kerlavage, AR, Bult, CJ, Tomb, JF, 
Dougherty, BA, Merrick, JM and et al. (1995) Whole-genome random sequencing and assembly 
of Haemophilus influenzae Rd. Science 269:496-512. 
Franklin, RE and Gosling, RG. (1953) Molecular configuration in sodium thymonucleate. Nature 171:740-
741. 
Gabriel, SB, Schaffner, SF, Nguyen, H, Moore, JM, Roy, J, Blumenstiel, B, Higgins, J, DeFelice, M, 
Lochner, A, Faggart, M, Liu-Cordero, SN, Rotimi, C, Adeyemo, A, Cooper, R, Ward, R, 
Lander, ES, Daly, MJ and Altshuler, D. (2002) The structure of haplotype blocks in the human 
genome. Science 296:2225-2229. 
61 
Gao, H, Boustany, RM, Espinola, JA, Cotman, SL, Srinidhi, L, Antonellis, KA, Gillis, T, Qin, X, Liu, S, 
Donahue, LR, Bronson, RT, Faust, JR, Stout, D, Haines, JL, Lerner, TJ and MacDonald, ME. 
(2002) Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal 
ceroid lipofuscinosis in man and mouse. Am J Hum Genet 70:324-335. 
Gardiner, M, Sandford, A, Deadman, M, Poulton, J, Cookson, W, Reeders, S, Jokiaho, I, Peltonen, L, 
Eiberg, H and Julier, C. (1990) Batten disease (Spielmeyer-Vogt disease, juvenile onset neuronal 
ceroid-lipofuscinosis) gene (CLN3) maps to human chromosome 16. Genomics 8:387-390. 
Gardiner, RM. (2000) The molecular genetic basis of the neuronal ceroid lipofuscinoses. Neurol Sci 
21:S15-19. 
Goebel, HH, Mole, SE and Lake, BD (1999) The Neuronal Ceroid Lipofuscinoses (Batten Disease). IOS 
Press. Amsterdam. 
Goebel, HH. (2000) Morphological aspects of the neuronal ceroid lipofuscinoses. Neurol Sci 21:S27-33. 
Golabek, AA, Kaczmarski, W, Kida, E, Kaczmarski, A, Michalewski, MP and Wisniewski, KE. (1999) 
Expression studies of CLN3 protein (battenin) in fusion with the green fluorescent protein in 
mammalian cells in vitro. Mol Genet Metab 66:277-282. 
Golabek, AA, Kida, E, Walus, M, Wujek, P, Mehta, P and Wisniewski, KE. (2002) Human tripeptidyl-
peptidase I: Biosynthesis, glycosylation and enzymatic processing in vivo. J Biol Chem 17:17. 
Griffin, JL, Muller, D, Woograsingh, R, Jowatt, V, Hindmarsh, A, Nicholson, JK and Martin, JE. (2002) 
Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by 
bioinformatics. Physiol Genomics 11:195-203. 
Guldberg, P, Henriksen, KF, Sipila, I, Guttler, F and de la Chapelle, A. (1995) Phenylketonuria in a low 
incidence population: molecular characterisation of mutations in Finland. J Med Genet 32:976-
978. 
Gupta, P, Soyombo, AA, Atashband, A, Wisniewski, KE, Shelton, JM, Richardson, JA, Hammer, RE and 
Hofmann, SL. (2001) Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in 
knockout mice. Proc Natl Acad Sci U S A 98:13566-13571. 
Haltia, M. (1975) Amauroottinen idiotia. Duodecim 91:312-316. 
Haskell, RE, Hughes, SM, Chiorini, JA, Alisky, JM and Davidson, BL. (2003) Viral-mediated delivery of 
the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous 
system. Gene Ther 10:34-42. 
Heinonen, O, Kyttälä, A, Lehmus, E, Paunio, T, Peltonen, L and Jalanko, A. (2000a) Expression of 
palmitoyl protein thioesterase in neurons. Mol Genet Metab 69:123-129. 
Heinonen, O, Salonen, T, Jalanko, A, Peltonen, L and Copp, A. (2000b) CLN-1 and CLN-5, genes for 
infantile and variant late infantile neuronal ceroid lipofuscinoses, are expressed in the embryonic 
human brain. J Comp Neurol 426:406-412. 
Hellsten, E, Vesa, J, Olkkonen, VM, Jalanko, A and Peltonen, L. (1996) Human palmitoyl protein 
thioesterase: evidence for lysosomal targeting of the enzyme and disturbed cellular routing in 
infantile neuronal ceroid lipofuscinosis. Embo J 15:5240-5245. 
Herrnstein, RJ and Murray, C (1994) The Bell Curve: The Reshaping of American Life by Differences in 
Intelligence. Free Press. New York. 
Hirokawa, T, Boon-Chieng, S and Mitaku, S. (1998) SOSUI: classification and secondary structure 
prediction system for membrane proteins. Bioinformatics 14:378-379. 
Holopainen, JM, Saarikoski, J, Kinnunen, PK and Jarvela, I. (2001) Elevated lysosomal pH in neuronal 
ceroid lipofuscinoses (NCLs). Eur J Biochem 268:5851-5856. 
Hästbacka, J, de la Chapelle, A, Kaitila, I, Sistonen, P, Weaver, A and Lander, E. (1992) Linkage 
disequilibrium mapping in isolated founder populations: diastrophic dysplasia in Finland. Nat 
Genet 2:204-211. 
International Batten Disease Consortium. (1995) Isolation of a novel gene underlying Batten disease, 
CLN3. Cell 82:949-957.Isosomppi, J, Heinonen, O, Hiltunen, JO, Greene, ND, Vesa, J, 
62 
Uusitalo, A, Mitchison, HM, Saarma, M, Jalanko, A and Peltonen, L. (1999) Developmental 
expression of palmitoyl protein thioesterase in normal mice. Brain Res Dev Brain Res 118:1-11. 
Isosomppi, J, Vesa, J, Jalanko, A and Peltonen, L. (2002) Lysosomal localization of the neuronal ceroid 
lipofuscinosis CLN5 protein. Hum Mol Genet 11:885-891. 
Jackson, DA, Symons, RH and Berg, P. (1972) Biochemical method for inserting new genetic information 
into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes 
and the galactose operon of Escherichia coli. Proc Natl Acad Sci U S A 69:2904-2909. 
Jallinoja, P (2002) Genetics, negotiated ethics and the ambiguities of moral choices. National Public 
Health Institute. Helsinki. 
Jansky, J. (1908) Dosud neposany pripad familiarni amauroticke idiotie komplikovane s hypoplasii 
mozeckovou. Sb Lek 13:165-196. 
Jolly, RD and Walkley, SU. (1999) Ovine ceroid lipofuscinosis (OCL6): postulated mechanism of 
neurodegeneration. Mol Genet Metab 66:376-380. 
Jutikkala, E and Pirinen, K (1996) A History of Finland. WSOY. Juva. 
Järvelä, I. (1991) Infantile neuronal ceroid lipofuscinosis (CLN1): linkage disequilibrium in the Finnish 
population and evidence that variant late infantile form (variant CLN2) represents a nonallelic 
locus. Genomics 10:333-337. 
Järvelä, I, Sainio, M, Rantamäki, T, Olkkonen, VM, Carpen, O, Peltonen, L and Jalanko, A. (1998) 
Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum 
Mol Genet 7:85-90. 
Järvelä, I, Lehtovirta, M, Tikkanen, R, Kyttälä, A and Jalanko, A. (1999) Defective intracellular transport 
of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet 8:1091-1098. 
Katz, ML, Gao, CL, Prabhakaram, M, Shibuya, H, Liu, PC and Johnson, GS. (1997) Immunochemical 
localization of the Batten disease (CLN3) protein in retina. Invest Ophthalmol Vis Sci 38:2375-
2386. 
Katz, ML, Liu, PC, Grob-Nunn, SE, Shibuya, H and Johnson, GS. (1999a) Characterization and 
chromosomal mapping of a mouse ortholog of the late-infantile ceroid-lipofuscinosis gene 
CLN2. Mamm Genome 10:1050-1053. 
Katz, ML, Shibuya, H, Liu, PC, Kaur, S, Gao, CL and Johnson, GS. (1999b) A mouse gene knockout 
model for juvenile ceroid-lipofuscinosis (Batten disease). J Neurosci Res 57:551-556. 
Kirveskari, E, Partinen, M and Santavuori, P. (2001) Sleep and its disturbance in a variant form of late 
infantile neuronal ceroid lipofuscinosis (CLN5). J Child Neurol 16:707-713. 
Kittles, RA, Perola, M, Peltonen, L, Bergen, AW, Aragon, RA, Virkkunen, M, Linnoila, M, Goldman, D 
and Long, JC. (1998) Dual origins of Finns revealed by Y chromosome haplotype variation. Am 
J Hum Genet 62:1171-1179. 
Klockars, T, Savukoski, M, Isosomppi, J, Laan, M, Järvelä, I, Petrukhin, K, Palotie, A and Peltonen, L. 
(1996) Efficient construction of a physical map by fiber-FISH of the CLN5 region: refined 
assignment and long-range contig covering the critical region on 13q22. Genomics 35:71-78. 
Klockars, T, Holmberg, V, Savukoski, M, Lander, ES and Peltonen, L. (1999) Transcript identification on 
the CLN5 region on chromosome 13q22. Human Genetics 105:51-56. 
Koike, M, Nakanishi, H, Saftig, P, Ezaki, J, Isahara, K, Ohsawa, Y, Schulz-Schaeffer, W, Watanabe, T, 
Waguri, S, Kametaka, S, Shibata, M, Yamamoto, K, Kominami, E, Peters, C, von Figura, K and 
Uchiyama, Y. (2000) Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin 
in mouse CNS neurons. J Neurosci 20:6898-6906. 
Kremmidiotis, G, Lensink, IL, Bilton, RL, Woollatt, E, Chataway, TK, Sutherland, GR and Callen, DF. 
(1999) The Batten disease gene product (CLN3p) is a Golgi integral membrane protein. Hum 
Mol Genet 8:523-531. 
63 
Krogh, A, Larsson, B, von Heijne, G and Sonnhammer, EL. (2001) Predicting transmembrane protein 
topology with a hidden Markov model: application to complete genomes. J Mol Biol 305:567-
580. 
Laitinen, T, Daly, MJ, Rioux, JD, Kauppi, P, Laprise, C, Petays, T, Green, T, Cargill, M, Haahtela, T, 
Lander, ES, Laitinen, LA, Hudson, TJ and Kere, J. (2001) A susceptibility locus for asthma-
related traits on chromosome 7 revealed by genome-wide scan in a founder population. Nat 
Genet 28:87-91. 
Lander, ES, Linton, LM, Birren, B, Nusbaum, C, Zody, MC, Baldwin, J, Devon, K, Dewar, K, Doyle, M, 
FitzHugh, W, Funke, R, Gage, D, Harris, K, Heaford, A, Howland, J, Kann, L, Lehoczky, J, 
LeVine, R, McEwan, P, McKernan, K, Meldrim, J, Mesirov, JP, Miranda, C, Morris, W, Naylor, 
J, Raymond, C, Rosetti, M, Santos, R, Sheridan, A, Sougnez, C, et al. (2001) Initial sequencing 
and analysis of the human genome. Nature 409:860-921. 
Lauronen, L, Huttunen, J, Kirveskari, E, Wikstrom, H, Sainio, K, Autti, T and Santavuori, P. (2002) 
Enlarged SI and SII somatosensory evoked responses in the CLN5 form of neuronal ceroid 
lipofuscinosis. Clin Neurophysiol 113:1491-1500. 
Lehtovirta, M, Kyttälä, A, Eskelinen, EL, Hess, M, Heinonen, O and Jalanko, A. (2001) Palmitoyl protein 
thioesterase (PPT) localizes into synaptosomes and synaptic vesicles in neurons: implications for 
infantile neuronal ceroid lipofuscinosis (INCL). Hum Mol Genet 10:69-75. 
Liu, CG, Sleat, DE, Donnelly, RJ and Lobel, P. (1998) Structural organization and sequence of CLN2, the 
defective gene in classical late infantile neuronal ceroid lipofuscinosis. Genomics 50:206-212. 
Lonka, L, Kyttälä, A, Ranta, S, Jalanko, A and Lehesjoki, AE. (2000) The neuronal ceroid lipofuscinosis 
CLN8 membrane protein is a resident of the endoplasmic reticulum. Hum Mol Genet 9:1691-
1697. 
Luiro, K, Kopra, O, Lehtovirta, M and Jalanko, A. (2001) CLN3 protein is targeted to neuronal synapses 
but excluded from synaptic vesicles: new clues to Batten disease. Hum Mol Genet 10:2123-
2131. 
Lönnqvist, T, Vanhanen, SL, Vettenranta, K, Autti, T, Rapola, J, Santavuori, P and Saarinen-Pihkala, UM. 
(2001) Hematopoietic stem cell transplantation in infantile neuronal ceroid lipofuscinosis. 
Neurology 57:1411-1416. 
March, PA, Wurzelmann, S and Walkley, SU. (1995) Morphological alterations in neocortical and 
cerebellar GABAergic neurons in a canine model of juvenile Batten disease. Am J Med Genet 
57:204-212. 
Margraf, LR, Boriack, RL, Routheut, AA, Cuppen, I, Alhilali, L, Bennett, CJ and Bennett, MJ. (1999) 
Tissue expression and subcellular localization of CLN3, the Batten disease protein. Mol Genet 
Metab 66:283-289. 
Maxam, AM and Gilbert, W. (1977) A new method for sequencing DNA. Proc Natl Acad Sci U S A 
74:560-564. 
Mendel, G. (1866) Versuche über Pflanzen-Hybriden. Verhandlungen des naturforschenden Vereines in 
Brünn 4:3-47. 
Mitchison, HM, Hofmann, SL, Becerra, CH, Munroe, PB, Lake, BD, Crow, YJ, Stephenson, JB, Williams, 
RE, Hofman, IL, Taschner, PEM, Martin, JJ, Philippart, M, Andermann, E, Andermann, F, 
Mole, SE, Gardiner, RM and O'Rawe, AM. (1998) Mutations in the palmitoyl-protein 
thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular 
osmiophilic deposits [published erratum appears in Hum Mol Genet 1998 Apr;7(4):765]. Human 
Molecular Genetics 7:291-297. 
Mitchison, HM, Bernard, DJ, Greene, ND, Cooper, JD, Junaid, MA, Pullarkat, RK, de Vos, N, Breuning, 
MH, Owens, JW, Mobley, WC, Gardiner, RM, Lake, BD, Taschner, PE and Nussbaum, RL. 
(1999) Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The 
Batten Mouse Model Consortium [corrected]. Neurobiol Dis 6:321-334. 
64 
Modrek, B and Lee, CJ. (2003) Alternative splicing in the human, mouse and rat genomes is associated 
with an increased frequency of exon creation and/or loss. Nat Genet 34:177-180. 
Mole, SE, Mitchison, HM and Munroe, PB. (1999) Molecular basis of the neuronal ceroid lipofuscinoses: 
Mutations in CLN1, CLN2, CLN3, and CLN5. Human Mutation 14:199-215. 
Mole, SE, Zhong, NA, Sarpong, A, Logan, WP, Hofmann, S, Yi, W, Franken, PF, van Diggelen, OP, 
Breuning, MH, Moroziewicz, D, Ju, W, Salonen, T, Holmberg, V, Jarvelä, I and Taschner, PE. 
(2001b) New mutations in the neuronal ceroid lipofuscinosis genes. Eur J Paediatr Neurol 5:7-
10. 
Mole, SE, Wheeler, RB, Sharp, JD and Cutler, D. (2003) Intracellular localisation of CLN6. Abstract at 
9th International Congress on Neuronal Ceroid Lipofuscinoses, Chicago.  
Moller, S, Croning, MD and Apweiler, R. (2001) Evaluation of methods for the prediction of membrane 
spanning regions. Bioinformatics 17:646-653. 
National Research Council (1996) Guide for the Care and Use of Laboratory Animals. Washington D.C. 
Nijssen, PC, Ceuterick, C, van Diggelen, OP, Elleder, M, Martin, JJ, Teepen, JL, Tyynela, J and Roos, 
RA. (2003) Autosomal dominant adult neuronal ceroid lipofuscinosis: a novel form of NCL with 
granular osmiophilic deposits without palmitoyl protein thioesterase 1 deficiency. Brain Pathol 
13:574-581. 
Nirenberg, MW. (1963) The genetic code: II. Sci Am 208:80-94. 
Norio, R. (2003a) Finnish Disease Heritage I: characteristics, causes, background. Hum Genet 112:441-
456. 
Norio, R. (2003b) Finnish Disease Heritage II: population prehistory and genetic roots of Finns. Hum 
Genet 112:457-469. 
Norio, R. (2003c) The Finnish Disease Heritage III: the individual diseases. Hum Genet 112:470-526. 
Pastinen, T, Perola, M, Ignatius, J, Sabatti, C, Tainola, P, Levander, M, Syvanen, AC and Peltonen, L. 
(2001) Dissecting a population genome for targeted screening of disease mutations. Hum Mol 
Genet 10:2961-2972. 
Pearce, DA, Ferea, T, Nosel, SA, Das, B and Sherman, F. (1999) Action of BTN1, the yeast orthologue of 
the gene mutated in Batten disease. Nat Genet 22:55-58. 
Peltonen, L, Jalanko, A and Varilo, T. (1999) Molecular genetics of the Finnish disease heritage. Hum 
Mol Genet 8:1913-1923. 
Peltonen, L, Palotie, A and Lange, K. (2000) Use of population isolates for mapping complex traits. Nat 
Rev Genet 1:182-190. 
Peltonen, L and McKusick, VA. (2001) Genomics and medicine. Dissecting human disease in the 
postgenomic era. Science 291:1224-1229. 
Peri, S and Pandey, A. (2001) A reassessment of the translation initiation codon in vertebrates. Trends 
Genet 17:685-687. 
Persaud-Sawin, DA, VanDongen, A and Boustany, RM. (2002) Motifs within the CLN3 protein: 
modulation of cell growth rates and apoptosis. Hum Mol Genet 11:2129-2142. 
Ranta, S, Zhang, YH, Ross, B, Lonka, L, Takkunen, E, Messer, A, Sharp, J, Wheeler, R, Kusumi, K, 
Mole, S, Liu, WC, Soares, MB, Bonaldo, MD, Hirvasniemi, A, de la Chapelle, A, Gilliam, TC 
and Lehesjoki, AE. (1999) The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant 
mice are associated with mutations in CLN8. Nature Genetics 23:233-236. 
Ranta, S, Topcu, M, Mole, SE and Lehesjoki, AE. (2003) Variant late infantile NCL in a subset of Turkish 
patients is allelic to Northern epilepsy. Abstract at 9th International Congress on Neuronal 
Ceroid Lipofuscinoses, Chicago.  
Rapola, J. (1993) Neuronal ceroid-lipofuscinoses in childhood. Perspect Pediatr Pathol 17:7-44. 
Rapola, J, Lähdetie, J, Isosomppi, J, Helminen, P, Penttinen, M and Järvelä, I. (1999) Prenatal diagnosis of 
variant late infantile neuronal ceroid lipofuscinosis (vLINCL[Finnish]; CLN5). Prenatal 
Diagnosis 19:685-688. 
65 
Regan, T (1983) The Case for Animal Rights. University of California Press. Berkeley and Los Angeles. 
Rider, JA and Rider, DL. (1988) Batten disease: past, present, and future. Am J Med Genet Suppl 5:21-26. 
Rouille, Y, Rohn, W and Hoflack, B. (2000) Targeting of lysosomal proteins. Semin Cell Dev Biol 
11:165-171. 
Rylova, SN, Amalfitano, A, Persaud-Sawin, DA, Guo, WX, Chang, J, Jansen, PJ, Proia, AD and 
Boustany, RM. (2002) The CLN3 gene is a novel molecular target for cancer drug discovery. 
Cancer Res 62:801-808. 
Sachs, B. (1896) A family form of idiocy, generally fatal, and associated with early blindness (amaurotic 
family idiocy). NY Med J 63:697-703. 
Saftig, P, Hetman, M, Schmahl, W, Weber, K, Heine, L, Mossmann, H, Koster, A, Hess, B, Evers, M, von 
Figura, K and et al. (1995) Mice deficient for the lysosomal proteinase cathepsin D exhibit 
progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. Embo J 
14:3599-3608. 
Saiki, RK, Scharf, S, Faloona, F, Mullis, KB, Horn, GT, Erlich, HA and Arnheim, N. (1985) Enzymatic 
amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of 
sickle cell anemia. Science 230:1350-1354. 
Saiki, RK, Gelfand, DH, Stoffel, S, Scharf, SJ, Higuchi, R, Horn, GT, Mullis, KB and Erlich, HA. (1988) 
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 
239:487-491. 
Sajantila, A and Pääbo, S. (1995) Language replacement in Scandinavia. Nat Genet 11:359-360. 
Sajantila, A, Salem, AH, Savolainen, P, Bauer, K, Gierig, C and Paabo, S. (1996) Paternal and maternal 
DNA lineages reveal a bottleneck in the founding of the Finnish population. Proc Natl Acad Sci 
U S A 93:12035-12039. 
Salonen, T, Hellsten, E, Horelli-Kuitunen, N, Peltonen, L and Jalanko, A. (1998) Mouse palmitoyl protein 
thioesterase: gene structure and expression of cDNA. Genome Res 8:724-730. 
Sanger, F and Coulson, AR. (1975) A rapid method for determining sequences in DNA by primed 
synthesis with DNA polymerase. J Mol Biol 94:441-448. 
Santavuori, P, Rapola, J, Sainio, K and Raitta, C. (1982) A variant of Jansky-Bielschowsky disease. 
Neuropediatrics 13:135-141. 
Santavuori, P, Westermarck, T, Rapola, J, Pohja, P, Moren, R, Lappi, M and Vuonnala, U. (1985) 
Antioxidant treatment in Spielmeyer-Sjögren's disease. Acta Neurol Scand 71:136-145. 
Santavuori, P. (1988) Neuronal ceroid-lipofuscinoses in childhood. Brain & Development 10:80-83. 
Santavuori, P, Heiskala, H, Westermarck, T, Sainio, K and Moren, R. (1988) Experience over 17 years 
with antioxidant treatment in Spielmeyer-Sjögren disease. Am J Med Genet Suppl 5:265-274. 
Santavuori, P, Rapola, J, Nuutila, A, Raininko, R, Lappi, M, Launes, J, Herva, R and Sainio, K. (1991) 
The spectrum of Jansky-Bielschowsky disease. Neuropediatrics 22:92-96. 
Santavuori, P, Lauronen, L, Kirveskari, E, Aberg, L, Sainio, K and Autti, T. (2000) Neuronal ceroid 
lipofuscinoses in childhood. Neurol Sci 21:S35-41. 
Sanyal, S and Ramaswami, M. (2002) Spinsters, synaptic defects, and amaurotic idiocy. Neuron 36:335-
338. 
Savukoski, M, Kestilä, M, Williams, R, Järvelä, I, Sharp, J, Harris, J, Santavuori, P, Gardiner, M and 
Peltonen, L. (1994) Defined chromosomal assignment of CLN5 demonstrates that at least four 
genetic loci are involved in the pathogenesis of human ceroid lipofuscinoses. American Journal 
of Human Genetics 55:695-701. 
Savukoski, M, Klockars, T, Holmberg, V, Santavuori, P, Lander, ES and Peltonen, L. (1998) CLN5, a 
novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile 
neuronal ceroid lipofuscinosis. Nature Genetics 19:286-288. 
Seigel, GM, Lotery, A, Kummer, A, Bernard, DJ, Greene, ND, Turmaine, M, Derksen, T, Nussbaum, RL, 
Davidson, B, Wagner, J and Mitchison, HM. (2002) Retinal pathology and function in a Cln3 
66 
knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease). Mol Cell 
Neurosci 19:515-527. 
Sharp, JD, Wheeler, RB, Lake, BD, Savukoski, M, Jarvela, IE, Peltonen, L, Gardiner, RM and Williams, 
RE. (1997) Loci for classical and a variant late infantile neuronal ceroid lipofuscinosis map to 
chromosomes 11p15 and 15q21-23. Hum Mol Genet 6:591-595. 
Sharp, JD, Wheeler, RB, Lake, BD, Fox, M, Gardiner, RM and Williams, RE. (1999) Genetic and physical 
mapping of the CLN6 gene on chromosome 15q21-23. Mol Genet Metab 66:329-331. 
Sharp, JD, Wheeler, RB, Schultz, RA, Joslin, JM, Mole, SE, Williams, RE and Gardiner, RM. (2001) 
Analysis of candidate genes in the CLN6 critical region using in silico cloning. Eur J Paediatr 
Neurol 5:29-31. 
Sharp, JD, Wheeler, RB, Parker, KA, Gardiner, RM, Williams, RE and Mole, SE. (2003) Spectrum of 
CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat 22:35-42. 
Singer, P (1975) Animal Liberation: A New Ethics for our Treatment of Animals. New York 
Review/Random House. New York. 
Sleat, DE, Donnelly, RJ, Lackland, H, Liu, CG, Sohar, I, Pullarkat, RK and Lobel, P. (1997) Association 
of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. 
Science 277:1802-1805. 
Sleat, DE, Gin, RM, Sohar, I, Wisniewski, K, Sklower-Brooks, S, Pullarkat, RK, Palmer, DN, Lerner, TJ, 
Boustany, RM, Uldall, P, Siakotos, AN, Donnelly, RJ and Lobel, P. (1999) Mutational analysis 
of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a 
neurodegenerative lysosomal storage disorder. American Journal of Human Genetics 64:1511-
1523. 
Sleat, DE, Wiseman, JA and Lobel, P. (2003) A mouse model for classical late-infantile neuronal ceroid 
lipofuscinosis (LINCL). Abstract at 9th International Congress on Neuronal Ceroid 
Lipofuscinoses, Chicago.  
Smith, LM, Sanders, JZ, Kaiser, RJ, Hughes, P, Dodd, C, Connell, CR, Heiner, C, Kent, SB and Hood, 
LE. (1986) Fluorescence detection in automated DNA sequence analysis. Nature 321:674-679. 
Sohar, I, Sleat, DE, Jadot, M and Lobel, P. (1999) Biochemical characterization of a lysosomal protease 
deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of 
an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal 
models. J Neurochem 73:700-711. 
Soyombo, AA and Hofmann, SL. (1997) Molecular cloning and expression of palmitoyl-protein 
thioesterase 2 (PPT2), a homolog of lysosomal palmitoyl-protein thioesterase with a distinct 
substrate specificity. J Biol Chem 272:27456-27463. 
Spielmeyer, W. (1905) Über familiäre amaurotische Idiotiee. Neurol Zentralbl 24:620-621. 
Steinfeld, R, Heim, P, von Gregory, H, Meyer, K, Ullrich, K, Goebel, HH and Kohlschutter, A. (2002) 
Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in 
patients with CLN2 mutations. Am J Med Genet 112:347-354. 
Suopanki, J, Tyynelä, J, Baumann, M and Haltia, M. (1999a) Palmitoyl-protein thioesterase, an enzyme 
implicated in neurodegeneration, is localized in neurons and is developmentally regulated in rat 
brain. Neurosci Lett 265:53-56. 
Suopanki, J, Tyynelä, J, Baumann, M and Haltia, M. (1999b) The expression of palmitoyl-protein 
thioesterase is developmentally regulated in neural tissues but not in nonneural tissues. Mol 
Genet Metab 66:290-293. 
Suopanki, J, Lintunen, M, Lahtinen, H, Haltia, M, Panula, P, Baumann, M and Tyynelä, J. (2002) Status 
epilepticus induces changes in the expression and localization of endogenous palmitoyl-protein 
thioesterase 1. Neurobiol Dis 10:247-257. 
Sweeney, ST and Davis, GW. (2002) Unrestricted synaptic growth in spinster-a late endosomal protein 
implicated in TGF-beta-mediated synaptic growth regulation. Neuron 36:403-416. 
67 
Svennerholm, L. (1962) The chemical structure of normal human brain and Tay Sachs gangliosidosis. 
Biochem Biophys Res Commun 9:436-441. 
Syvänen, AC, Aalto-Setala, K, Kontula, K and Soderlund, H. (1989) Direct sequencing of affinity-
captured amplified human DNA application to the detection of apolipoprotein E polymorphism. 
FEBS Lett 258:71-74. 
Tahvanainen, E, Ranta, S, Hirvasniemi, A, Karila, E, Leisti, J, Sistonen, P, Weissenbach, J, Lehesjoki, AE 
and de la Chapelle, A. (1994) The gene for a recessively inherited human childhood progressive 
epilepsy with mental retardation maps to the distal short arm of chromosome 8. Proc Natl Acad 
Sci U S A 91:7267-7270. 
The C. elegans Sequencing Consortium. (1998) Genome sequence of the nematode C. elegans: a platform 
for investigating biology. Science 282:2012-2018. 
Tyynelä, J, Palmer, DN, Baumann, M and Haltia, M. (1993) Storage of saposins A and D in infantile 
neuronal ceroid-lipofuscinosis. FEBS Lett 330:8-12. 
Tyynelä, J, Suopanki, J, Santavuori, P, Baumann, M and Haltia, M. (1997) Variant late infantile neuronal 
ceroid-lipofuscinosis: pathology and biochemistry. Journal of Neuropathology & Experimental 
Neurology 56:369-375. 
Tyynelä, J, Sohar, I, Sleat, DE, Gin, RM, Donnelly, RJ, Baumann, M, Haltia, M and Lobel, P. (2000) A 
mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with 
profound neurodegeneration. Embo J 19:2786-2792. 
Tyynelä, J and Suopanki, J. (2000) Biochemical aspects of neuronal ceroid lipofuscinoses. Neurol Sci 
21:S21-25. 
Walkley, SU and March, PA. (1993) Biology of neuronal dysfunction in storage disorders. J Inherit Metab 
Dis 16:284-287. 
Vandenplas, S, Wiid, I, Grobler-Rabie, A, Brebner, K, Ricketts, M, Wallis, G, Bester, A, Boyd, C and 
Mathew, C. (1984) Blot hybridisation analysis of genomic DNA. J Med Genet 21:164-172. 
Varilo, T, Savukoski, M, Norio, R, Santavuori, P, Peltonen, L and Järvelä, I. (1996) The age of human 
mutation: genealogical and linkage disequilibrium analysis of the CLN5 mutation in the Finnish 
population. American Journal of Human Genetics 58:506-512. 
Varilo, T, Laan, M, Hovatta, I, Wiebe, V, Terwilliger, JD and Peltonen, L. (2000) Linkage disequilibrium 
in isolated populations: Finland and a young sub-population of Kuusamo. Eur J Hum Genet 
8:604-612. 
Venter, JC, Adams, MD, Myers, EW, Li, PW, Mural, RJ, Sutton, GG, Smith, HO, Yandell, M, Evans, CA, 
Holt, RA, Gocayne, JD, Amanatides, P, Ballew, RM, Huson, DH, Wortman, JR, Zhang, Q, 
Kodira, CD, Zheng, XH, Chen, L, Skupski, M, Subramanian, G, Thomas, PD, Zhang, J, Gabor 
Miklos, GL, Nelson, C, Broder, S, Clark, AG, Nadeau, J, McKusick, VA, Zinder, N, et al. 
(2001) The sequence of the human genome. Science 291:1304-1351. 
Verkruyse, LA and Hofmann, SL. (1996) Lysosomal targeting of palmitoyl-protein thioesterase. J Biol 
Chem 271:15831-15836. 
Vesa, J, Hellsten, E, Verkruyse, LA, Camp, LA, Rapola, J, Santavuori, P, Hofmann, SL and Peltonen, L. 
(1995) Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid 
lipofuscinosis. Nature 376:584-587. 
Vesa, J, Chin, MH, Oelgeschlager, K, Isosomppi, J, DellAngelica, EC, Jalanko, A and Peltonen, L. (2002) 
Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein 
with CLN2 and CLN3. Mol Biol Cell 13:2410-2420. 
Vines, DJ and Warburton, MJ. (1999) Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are 
deficient in lysosomal tripeptidyl peptidase I. FEBS Lett 443:131-135. 
Vogt, H. (1905) Über familiäre amaurotische und verwandte Krankheitsbilder. Psychiatr Neurol 18:161-
171. 
68 
Waterston, RH, Lindblad-Toh, K, Birney, E, Rogers, J, Abril, JF, Agarwal, P, Agarwala, R, Ainscough, R, 
Alexandersson, M, An, P, Antonarakis, SE, Attwood, J, Baertsch, R, Bailey, J, Barlow, K, Beck, 
S, Berry, E, Birren, B, Bloom, T, Bork, P, Botcherby, M, Bray, N, Brent, MR, Brown, DG, 
Brown, SD, Bult, C, Burton, J, Butler, J, Campbell, RD, Carninci, P, et al. (2002) Initial 
sequencing and comparative analysis of the mouse genome. Nature 420:520-562. 
Watson, JD and Crick, FHC. (1953) A structure for deoxyribose nucleic acid. Nature 171:737-738. 
Weissenbach, J, Gyapay, G, Dib, C, Vignal, A, Morissette, J, Millasseau, P, Vaysseix, G and Lathrop, M. 
(1992) A second-generation linkage map of the human genome. Nature 359:794-801. 
Wheeler, RB, Sharp, JD, Schultz, RA, Joslin, JM, Williams, RE and Mole, SE. (2002) The gene mutated 
in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a 
novel predicted transmembrane protein. Am J Hum Genet 70:537-542. 
Williams, R, Santavuori, P, Peltonen, L, Gardiner, RM and Järvelä, I. (1994) A variant form of late 
infantile neuronal ceroid lipofuscinosis (CLN5) is not an allelic form of Batten (Spielmeyer-
Vogt-Sjogren, CLN3) disease: exclusion of linkage to the CLN3 region of chromosome 16. 
Genomics 20:289-290. 
Williams, RS, Lott, IT, Ferrante, RJ and Caviness, VS, Jr. (1977) The cellular pathology of neuronal 
ceroid-lipofuscinosis. A golgi- electronmicroscopic study. Arch Neurol 34:298-305. 
Winter, E and Ponting, CP. (2002) TRAM, LAG1 and CLN8: members of a novel family of lipid-sensing 
domains? Trends Biochem Sci 27:381-383. 
Yoshikawa, M, Uchida, S, Ezaki, J, Rai, T, Hayama, A, Kobayashi, K, Kida, Y, Noda, M, Koike, M, 
Uchiyama, Y, Marumo, F, Kominami, E and Sasaki, S. (2002) CLC-3 deficiency leads to 
phenotypes similar to human neuronal ceroid lipofuscinosis. Genes Cells 7:597-605. 
Zeman, W and Donahue, S. (1963) Fine structure of the lipid bodies in juvenile amaurotic idiocy. Acta 
Neuropathol 3:144-149. 
Zeman, W and Dyken, P. (1969) Neuronal ceroid-lipofuscinosis (Batten's disease). Pediatrics 44:570-583. 
 
